REF_AREA,Reference area,MEASURE,Measure,UNIT_MEASURE,Unit of measure,PHARMACEUTICAL,Pharmaceutical,TIME_PERIOD,OBS_VALUE
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,12.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,13
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,13.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,13.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,12.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,14
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,14.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,15.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,15.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,18.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,5.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,5.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,5.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,5.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,4.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,4.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,4.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,3.7
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,10.6
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,11.3
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,11.1
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,11.5
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,12.1
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,12.8
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,13.1
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,12.7
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,12.1
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,10.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,8.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,8.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,7.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,6.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,5.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,5.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,5.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,5.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,0.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,0.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,0.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,0.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,0.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,15.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,14.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,14.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,16.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,16.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,16.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,13.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,11.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,10.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,11.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2023,13.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,18
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,20
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,21.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,24.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,26.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,27.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,29
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,31.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,33.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,33
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,2.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,2.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,2.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,3.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,3.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,3.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,7.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,7.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,7.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,8.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,7.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,7.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,7.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,7.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,7.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,7.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,41.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,43.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,43.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,43.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,43.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,43.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,43.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,42.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,42.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,41.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,40.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,22
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,21.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,21.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,21
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,21
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,21.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,21.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,17.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,17.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,21.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,118.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,125.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,127.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,138.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,152.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,161
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,170.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,176.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,190
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,5.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,5.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,5.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,7.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,7.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,8.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,8.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,8.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,8.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,35
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,27.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,24.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,23.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,24.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,24.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,26
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,27.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,27.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,30.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,7.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,7.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,7.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,7.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,7.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,7.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,7.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,1.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,1.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,2.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,1.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,2.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,2.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,2.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,2.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,2.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,30.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,33.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,37.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,40.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,42
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,43.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,46.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,52.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,54.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,55
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,54.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,1.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,1.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,1.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,2.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,2.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,2.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,2.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,3.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,3.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,3.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,84.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,82.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,82.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,80.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,77.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,73.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,73.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,74.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,74.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,73.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,78.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,87.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,92.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,95.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,99.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,103.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,109.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,123.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,131
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,138.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,148.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,154.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,6.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,7.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,8.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,8.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,8.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,9.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,10.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,16.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,13.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,14.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,16.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,17.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,18.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,19.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,19.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,21.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,22.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,23.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,7.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,7.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,7.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,7.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,8.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,9.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,8.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,9.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,9.5
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,30.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,26.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,26.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,25.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,25.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,25.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,24.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,24.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,25.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,25.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,24.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,31.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,32.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,35.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,40.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,45.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,50.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,58
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,62.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,64.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,68.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,5.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,6.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,7.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,7.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,7.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,7.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,9.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,10.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,0.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,0.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,0.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,1.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,5.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,5.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,5.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,5.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,4.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,4.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,4.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,4.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,5.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,6
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,85
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,87.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,90.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,100.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,104.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,108.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,114.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,122
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,130.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,134
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,133
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,20.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,20.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,20.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,18.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,18.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,18
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,17.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,16.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,17.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,15.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,11.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,10.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,9.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,8.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,8.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,9.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,10
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,10.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,10.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,11.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,45.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,52.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,59.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,46.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,39.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,47.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,48
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,73.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,77.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,79.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,78.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,10.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,10
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,9.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,10.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,10.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,11.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,12.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,13.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,15
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,32.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,33.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,31
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,32
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,32.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,33
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,35
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,33.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,35.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,27.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,37.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,75.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,75.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,71.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,67.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,64.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,60.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,59.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,56.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,57
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,54.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,8.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,8.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,7.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,7.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,7.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,7.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,7.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,6.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,5.3
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,9.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,9.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,59.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,57.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,56.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,55.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,53.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,51.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,50.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,47.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,36.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,16.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,12.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,12.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,12.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,12.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,11.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,11.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,11.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,10.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,9.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,10.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,2.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,2.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,31.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,30.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,28.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,30.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,28.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,27.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,5.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,5.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,4.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,4.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,4.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,3.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,3.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,3.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,3.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,4.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,4.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,4.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,4.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,4.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,5.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,6.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,7.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,7.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,2.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,3.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,3.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,3.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,3.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,60.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,63.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,66.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,68.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,68.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,68.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,69.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,72.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,74.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,75.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,76.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,17.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,18
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,18.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,19
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,18.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,19.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,19.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,15.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,15.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,18.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,32.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,37.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,40.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,45.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,51.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,60.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,67.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,75.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,86.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,91
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,11.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,11.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,11.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,11.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,11.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,11.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,12
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,11.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,11.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,12.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,82.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,82.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,84.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,85.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,88.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,88.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,90.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,92.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,107.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,102.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,97
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,2.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,2.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,3.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,3.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,4.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,4.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,5.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,28.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,27.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,27.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,29.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,29.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,23.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,20.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,21.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,20.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,20.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,15.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,15.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,16.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,19.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,17
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,17.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,18.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,19
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,22.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,18.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,36.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,47.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,51.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,38.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,39
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,38.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,35.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,29.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,32
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,31.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,3.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,17.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,18.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,20.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,22.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,23.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,24
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,26
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,29.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,30.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,35.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,50.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,51.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,52.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,53.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,53.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,54.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,55.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,43.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,39.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,1.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,1.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,1.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,1.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,1.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,1.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,1.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,6.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,6.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,6.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,7.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,7.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,7.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,7.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,7.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,7.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,13.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,13.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,14.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,13.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,13.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,15.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,15.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,16.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,16.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,20.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,141.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,143.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,145.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,147.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,150.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,152.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,158.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,160.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,165
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,170.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,173.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,21
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,22.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,23.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,26
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,27.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,28
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,29.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,29.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,31.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,31.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,8.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,8.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,8.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,8.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,7.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,7.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,8.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,7.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,8.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,7.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,6.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,8.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,9.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,8.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,8.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,24.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,26.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,26.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,26.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,26.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,26.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,27.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,27
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,26.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,25.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,25.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,30.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,30
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,30.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,28.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,28.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,29.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,29.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,25.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,24.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,30.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,18.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,18.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,17.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,17.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,17.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,17.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,17.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,19.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,20.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,21.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,1.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,1.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,1.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,1.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,144.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,144.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,143.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,143.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,143.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,143.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,143.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,142
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,143
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,142.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,24
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,25.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,24.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,22.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,21.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,22.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,23.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,24.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,25.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,24.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,43.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,44.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,48.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,51.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,54.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,61
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,65.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,67.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,56.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,56.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,57.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,58
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,57.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,57.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,56.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,57.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,58.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,61.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,63.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,63.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,43.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,41.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,38.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,36.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,34
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,33.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,35.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,37
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,37.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,41.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,96.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,105.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,110.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,114.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,117.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,123.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,125.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,128.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,135.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,143.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,147.8
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,26.8
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,26.6
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,28.1
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,24.4
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,24.5
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,25.1
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,25.8
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,25.2
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,25.7
ROU,Romania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,27.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,55.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,59.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,62.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,64.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,62.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,61.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,59.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,60
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,66.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,68.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,42.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,43.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,45.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,18.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,17.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,17.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,16.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,16
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,15.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,17.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,10.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,10.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,10.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,10.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,10.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,10.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,12.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,12.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,12.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,13.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,7.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,7.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,7.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,8.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,8.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,9.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,10.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,11.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,13.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,16.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,10.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,8.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,7.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,7.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,8.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,9.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,9.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,10.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,11.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,14.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,15.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,15.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,14.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,14.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,14.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,14.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,11.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,11.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,14.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,20.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,17.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,15.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,15.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,14
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,14.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,13.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,14.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,15.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,16.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,36.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,36.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,32.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,28.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,27.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,26.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,27.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,27.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,26.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,25.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,6.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,6.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,6.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,6.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,6.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,6.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,6.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,6.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,6.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,6.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,26
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,24.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,23.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,26.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,24.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,24.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,24.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,24.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,26.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,21.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,2.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,2.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,2.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,2.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,2.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,2.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,18.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,17.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,16.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,16.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,16.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,16.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,16.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,6.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,8.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,8.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,8.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,8.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,8.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,8.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,7.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,8.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,8.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,8.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,46.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,44.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,43.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,44.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,40.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,38.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,39.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,35.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,37
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,37
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,16.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,17.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,15.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,19.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,20.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,21.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,24.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,25.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,27.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,22.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,73.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,74.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,75.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,78.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,80.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,82.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,83.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,85.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,87.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,91.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,12.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,11.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,10.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,7.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,5.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,5.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,5.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,5.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,5.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,5.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,42.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,40.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,40.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,40.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,40
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,38.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,37.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,35
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,34.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,37.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,34.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,11.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,13.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,13.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,15.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,15.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,16.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,16.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,17.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,19.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,76.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,78.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,80.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,81.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,86
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,90.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,95.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,99.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,104.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,6.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,6.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,7.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,8.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,8.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,8.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,8.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,8.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,11.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,44.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,45.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,47.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,49.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,50.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,49.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,49.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,51.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,51.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,14.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,14.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,15
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,15.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,15.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,15.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,16.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,17.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,18.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,21.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,15
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,18.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,23.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,29.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,32.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,38.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,44.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,45.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,48
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,52.8
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,15.9
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,15.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,2.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,2.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,2.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,2.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,2.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,2.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,2.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,50
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,50.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,53.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,48.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,48.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,48.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,47.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,44.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,54.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,54.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,6.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,6.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,7.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,7.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,7.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,6.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,6.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,5.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,5.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,6.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,6.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,6.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,6.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,6.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,7.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,7.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,7.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,8.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,51.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,58.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,76.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,72.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,66.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,89.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,114
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,101.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,157.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,136.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,111.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,55.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,56.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,58.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,60.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,62.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,64.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,67.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,70.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,73.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,80.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,88.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,17.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,16.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,15.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,14.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,13.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,13
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,12.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,12
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,11.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,11.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,6.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,6.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,6.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,5.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,5.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,5.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,5.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,5.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,5.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,33.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,36.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,39
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,41.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,43.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,44.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,46.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,54.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,52
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,55.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,85.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,92
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,99.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,106.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,115.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,124.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,134.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,144.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,155.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,172.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,187.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.1
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,8.8
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,8.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,0.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,11.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,10.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,10
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,10.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,9.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,8.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,7.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,7.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,6.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,6.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,5.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,9.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,9.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,9.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,9.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,9.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,10.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,11.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,12.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,12.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,37.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,36.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,35.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,35.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,34.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,34.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,33.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,33
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,32.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,33.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,31.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,97.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,97.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,97.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,95.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,93.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,92.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,89.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,84.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,85.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,84.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,79.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,1.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,1.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,1.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,1.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,1.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,1.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,1.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,53.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,52.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,54.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,56.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,55.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,55.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,56.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,52.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,53.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,56.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,56.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,28.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,30.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,31.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,34.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,37.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,40.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,45
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,48.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,47.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,50.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,24
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,23.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,25.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,27.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,29.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,32.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,33.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,35.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,37.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,41.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,9.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,8.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,8.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,9.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,9.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,9.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,10.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,11.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,13.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,11
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,7.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,7.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,7.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,8.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,8.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,8.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,9.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,9.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,9.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,11.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,10.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,9.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,8.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,9.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,11
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,11.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,11.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,12.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,12.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,13.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,14.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,14.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,15.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,16
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,16.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,17.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,17.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,17.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,20.2
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,18.6
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,20
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,20.2
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,19.2
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,20.5
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,21.1
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,20.7
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,22.7
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,24.4
BGR,Bulgaria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,25.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,2.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,2.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,2.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,2.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,2.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,2.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,49.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,49.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,45.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,44.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,42.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,42.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,44.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,41.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,45.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,51.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,52.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,15
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,14.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,13.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,14.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,14.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,15.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,17
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,17.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,17.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,40.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,43.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,44.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,47.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,50
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,53.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,56.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,59
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,58.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,61.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,47.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,45.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,45.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,43.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,40.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,41.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,40.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,37.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,36.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,35.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,5.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,5.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,5.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,5.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,5.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,5.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,5.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,5.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,4.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,4.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,4.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,4.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,4.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,4.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,4.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,4.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,4.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,5.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,37.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,35.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,34.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,33.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,31.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,27.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,26.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,25.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,25.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,26.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,186.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,191
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,193.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,198.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,203
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,204.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,206.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,205.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,227
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,221.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,18.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,18.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,18.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,19.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,21.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,23.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,25.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,33
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,36
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,41
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,1.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,2.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,2.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,2.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,21.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,21.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,21
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,20.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,20.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,19.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,18.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,18.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,19
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,17.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,18.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,13.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,13.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,13.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,13.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,14
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,14.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,15.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,6.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,6.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,7.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,112.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,113.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,113.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,112.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,112.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,113.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,114
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,115.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,117.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,120.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,122.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,7.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,8.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,8.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,9.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,9.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,10
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,10.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,10.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,10.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,14.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,15.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,16.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,18.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,17.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,15.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,15.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,15
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,14.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,14.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,70.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,69.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,68.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,66.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,65.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,65.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,64.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,65.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,63.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,11.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,11.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,11.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,11.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,10.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,10.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,10.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,8.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,9.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,11.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,21.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,22.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,22.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,23.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,26.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,26.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,25.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,17.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,18.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,19.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,22.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,22.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,22
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,21.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,20.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,20.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,20
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,19.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,18.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,18.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,3.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,4.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,4.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,4.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,4.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,4.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,4.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,4.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,4.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,4.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,22.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,23.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,24.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,24.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,25.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,27.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,27.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,28
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,27.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,28.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,25.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,8.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,8.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,8.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,9.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,8.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,8.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,8.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,7.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,3.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,3.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,3.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,3.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,4.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,5.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,4.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,21.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,21.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,22.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,23.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,22.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,22.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,31.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,27.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,26.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,40.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,40.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,41.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,45.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,45.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,44.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,44.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,43.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,43.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,42.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,41.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,20.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,21.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,20.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,19.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,19.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,18.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,18.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,19.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,17
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,16.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,4.8
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,4.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,0
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,43.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,47.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,51.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,53.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,58.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,64.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,69.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,79.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,88.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,102.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,113.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,31.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,30.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,29.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,28.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,28.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,28
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,27
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,26.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,25.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,26.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,62.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,64.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,67.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,68.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,67.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,70.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,74.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,77.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,79.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,85.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,85.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,37.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,37.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,37.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,37.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,35.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,34.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,33.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,28.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,29.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,30.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,6.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,6.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,6.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,6.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,6.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,6.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,5.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,5.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,5.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,1.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,1.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,1.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,1.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,1.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,1.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,1.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,1.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,1.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,35.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,35.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,35.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,35.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,35.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,35
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,35.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,34.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,33.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,33.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,5.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,5.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,5.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,5.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,5.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,5.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,5.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,5.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,1.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,1.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,1.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,1.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,1.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,1.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,1.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,1.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,6.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,6.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,6.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,6.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,6.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,6.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,6.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,6.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,6.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,6.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,17.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,20.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,19.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,21.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,21.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,24.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,25.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,27.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,30
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,31
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,8.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,7.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,6.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,6.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,6.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,5.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,4.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,4.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,4.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,20.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,22.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,23.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,24.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,25.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,27.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,29.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,32.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,33.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,38.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,57.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,56.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,55.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,55.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,54.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,54.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,54.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,52.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,52.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,51.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,4.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,4.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,4.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,4.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,4.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,5.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,4.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,51.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,51.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,51.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,51.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,51.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,51.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,54.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,54.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,57.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,61.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,6.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,6.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,6.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,7.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,7.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,8.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,10.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,11.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,16.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,3.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,3.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,3.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,3.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,3.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,3.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,3.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,12
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,11.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,12.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,12
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,11.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,11.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,11.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,10.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,10.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,12.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,5.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,5.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,4.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,4.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,3.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,3.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,3.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,3.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,3.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,20.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,25.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,30.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,36.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,41.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,50
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,53.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,58
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,59.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,59.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,31
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,52.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,50.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,42
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,38.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,39.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,35.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,73.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,62.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,62.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,71.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,43.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,46.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,48.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,49.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,52.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,52.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,56
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,60.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,60.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,60.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,61
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,15.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,19.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,21.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,29.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,37.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,46.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,58.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,75.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,92.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,114.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,76.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,77.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,77.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,78
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,77.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,76
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,68.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,62.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,64
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,64.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,94.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,93.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,93.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,92.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,90.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,90.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,95.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,94
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,100.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,109.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,16.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,15
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,12.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,11.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,11.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,11.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,11
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,11
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,11.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,11.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,7.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,8.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,8.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,8.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,8.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,16.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,16.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,15.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,15.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,17.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,4.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,4.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,4.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,4.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,4.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,4.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,4.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,4.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,4.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,3.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,3.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,3.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,4.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,3.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,19.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,20.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,20.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,19.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,16.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,16.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,18.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,62.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,61.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,62
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,62.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,62.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,63
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,64.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,65
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,65.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,68.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,71.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,44.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,39.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,36.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,34.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,32.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,31.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,30.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,29.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,28.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,27.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,51.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,50.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,48.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,47.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,46.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,44.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,43.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,42.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,40.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,39.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,93.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,98.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,103.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,106.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,109.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,111.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,114.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,115.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,118.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,118.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,52.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,56.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,56.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,56.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,56.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,56.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,56.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,58.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,60.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,59.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,58
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,46.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,49.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,44.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,44.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,44.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,46.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,48.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,50.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,52.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,43.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,60.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,58.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,61.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,64.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,66.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,72.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,75.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,79.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,91.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,96.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,94.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,8.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,7.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,7.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,7.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,7.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,7.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,7.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,6.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,6.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,39.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,39.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,39.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,39.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,37.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,38.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,38.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,39.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,34.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,2.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,2.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,1.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,2.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,2.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,2.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,24.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,23.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,19.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,19.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,19.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,20
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,21.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,23.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,22.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,23.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,4.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,5.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,5.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,5.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,5.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,5.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,5.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,44.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,42.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,42.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,40.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,37.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,35.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,34.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,32.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,32.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,27.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,26.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,101.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,105.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,106.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,109.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,108.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,112.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,124.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,133.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,142.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,154.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,161.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,90.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,96.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,87.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,79.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,81.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,83.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,85.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,90.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,93.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,93.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,10.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,11.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,11.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,12.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,12.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,11.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,12.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,12.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,12.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,12.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,164
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,168.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,173.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,177.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,179.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,182.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,188.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,194.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,198
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,205
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,210.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,98.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,100.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,103.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,110.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,114.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,123.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,133.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,140.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,150.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,157.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,162.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,2.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,2.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,2.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,2.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,2.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,15.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,17.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,15.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,16.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,17.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,17.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,18.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,19.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,20.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,23.1
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,117.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,121.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,118.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,138.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,139.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,155.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,113.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,115.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,125.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,133
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,138.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,142
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,146
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,153.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,161.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,157.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,164.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,31.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,29.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,30.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,29.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,27
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,26.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,25.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,27.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,26.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,29.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,160.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,155.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,158.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,159.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,161.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,157.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,172
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,168
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,173.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,175.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,20.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,21.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,23.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,24.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,26.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,26.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,27.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,28.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,29.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,32.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,4.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,4.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,4.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,4.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,4.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,5.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,6.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,6.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,6.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,21.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,20.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,21.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,21.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,21.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,22.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,24.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,26
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,26.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,29
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,7.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,8.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,7.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,7.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,6.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,6.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,6.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,6.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,3.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,3.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,4.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,4.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,3.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,3.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,3.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,3.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,3.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,3.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,3.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,3.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,3.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,3.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,3.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,3.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,3.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,3.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,3.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,3.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,3.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,3.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,13.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,13.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,13.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,13
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,13.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,13.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,13
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,10.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,10.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,12.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,20.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,20
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,17.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,14.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,14.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,13.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,14.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,13.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,13.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,14.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,28.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,27.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,23.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,22
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,21.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2023,26.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,4.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,5.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,5.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,6.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,6.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,6.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,7.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,7.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,7.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,1.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,2.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,39.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,39.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,39.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,39.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,39.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,40.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,41.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,41.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,41.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,44
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,45.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,35.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,38.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,40
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,38.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,39.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,41.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,42.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,42.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,44.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,47.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,7.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,8.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,8.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,8.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,8.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,9.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,10.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,11.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,12.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,20.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,48.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,48.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,49
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,51.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,50
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,48.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,51.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,50.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,50.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,50.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,182.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,176.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,185.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,223.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,239.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,247.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,260.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,274.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,280.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,280.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,30.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,34.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,37.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,41.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,45.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,48.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,51.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,53.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,56
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,60.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,1.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,1.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,2.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,24.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,24
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,24.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,24.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,22.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,22.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,21.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,16.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,17.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,20.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,15.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,13.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,12.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,12.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,11.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,12.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,12.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,13.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,14.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,15.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,27
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,27.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,26.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,28.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,28.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,31.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,33.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,34.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,35.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,38.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,27.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,26.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,29.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,29.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,28.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,32.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,35.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,38.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,43.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,48.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,51.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,50.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,51.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,51.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,53.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,51.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,51.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,51.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,51.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,10.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,10.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,10
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,10.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,10.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,10.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,10.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,10.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,10.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,10.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,3.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,3.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,3.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,2.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,11.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,11.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,12.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,12.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,12.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,13.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,14.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,15
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,14.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,14.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,16.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,17.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,18.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,19.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,20.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,22.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,24.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,26.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,27.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,28.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,29.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,27.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,25
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,25.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,26.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,27.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,29.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,30.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,31.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,32.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,121.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,125.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,124.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,125.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,123.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,125.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,127.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,128.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,134.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,138.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,136.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,24.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,26.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,28.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,32.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,34.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,36.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,42.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,44
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,50.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,57.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,5.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,5.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,6.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,6.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,6.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,6.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,6.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,7.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,8.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,12.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,12
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,82.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,83.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,84.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,85.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,84.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,72.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,74.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,74.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,90
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,96.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,73.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,73
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,73.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,73.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,70.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,71.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,70.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,62
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,60.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,64.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,63
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,1.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,1.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,1.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,1.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,1.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,1.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,1.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,1.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,1.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,33.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,33.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,33.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,34.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,36.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,43.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,44
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,43.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,44.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,38.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,46.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,45.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,45.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,40
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,41.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,41.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,318.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,329.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,335.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,341.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,342.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,357.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,377
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,389.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,397.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,404.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,1.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,1.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,1.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,1.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,2.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,2.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,2.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,2.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,1.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,1.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,34.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,34.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,35.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,37.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,37.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,34.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,34.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,45.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,49.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,52
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,56.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,10.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,10.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,10.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,10.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,10.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,11.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,12.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,11.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,11.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,9.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,5.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,5.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,5.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,5.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,5.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,5.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,5.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,5.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,5.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,58.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,54
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,51.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,50.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,46.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,45.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,43.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,46.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,46.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,42
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,59.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,60.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,60.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,60.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,61
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,61.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,62
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,63.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,63.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,63.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,34.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,31.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,31
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,31.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,29.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,29.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,30
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,31.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,31.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,33.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,3.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,3.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,42.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,45.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,47.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,49
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,51.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,54.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,55.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,56.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,57
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,58.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,55.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,17.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,17.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,17.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,18.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,18.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,19.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,9.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,9.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,9.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,9.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,9.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,9.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,10.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,8.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,8.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,10.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,4.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,4.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,4.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,3.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,3.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,3.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,27.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,27.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,28.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,28.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,28.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,29.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,29.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,30.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,29.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,30.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,30.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,2.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,2.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,2.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,2.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,6.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,6.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,6.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,6.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,5.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,5.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,5.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,4.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,4.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,4.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,7.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,8.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,8.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,8.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,8.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,9.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,10.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,12
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,60.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,60.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,60.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,60.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,60.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,59.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,58.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,59.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,55.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,54.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,65
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,66.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,68
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,70
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,71
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,72.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,75.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,78
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,77.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,81.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,44.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,43
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,45.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,50.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,52.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,52.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,55.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,54.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,54.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,54.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,41.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,42.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,43.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,43.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,45.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,46.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,48.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,50.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,50
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,51.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,53.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,33.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,34.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,36.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,39
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,39.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,45.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,46
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,47.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,48.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,18.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,17.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,17.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,14.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,14.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,14.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,14.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,15.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,15.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,15.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,12
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,10.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,10.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,9.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,8.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,7.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,8.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,8.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,8.8
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,21.6
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,21
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,23
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,22
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,21
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,22.4
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,22.8
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,18.6
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,17.8
IRL,Ireland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,23.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,1.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,1.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,1.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,1.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,1.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,2.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,4.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,4.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,3.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,136.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,138.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,126.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,126.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,128.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,136.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,145.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,145.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,156.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,126.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,124.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,2.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,2.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,2.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,2.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,2.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,2.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,6.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,4.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,4.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,4.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,3.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,4.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,4.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,4.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,5.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,1.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,1.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,1.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,1.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,58.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,58.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,59.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,59.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,60.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,60.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,61.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,63.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,62.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,62.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,62.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,22.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,22.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,22.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,23.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,23.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,24.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,26.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,28.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,26.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,28.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,29.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,36.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,35.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,33.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,47.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,42.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,43.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,63.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,63.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,68.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,57.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,80.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,82.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,83.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,85.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,87.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,90
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,92.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,95.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,96.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,100.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,63.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,64.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,65.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,66.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,67.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,67.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,68.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,68.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,67.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,68.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,67.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,58.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,58.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,58.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,79
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,81.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,84.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,86.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,104.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,124.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,126.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,158.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,1.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,1.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,1.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,1.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,1.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,1.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,1.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,1.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,2
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,24.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,22.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,21.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,21.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,19.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,19.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,22.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,22.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,22.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,23
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,28.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,32.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,35
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,37.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,39.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,46
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,48
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,46.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,50.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,55.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,56.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,7.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,8.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,10.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,12.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,12.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,10.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,14.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,15.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,14.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,18.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,26.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,27.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,27.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,29.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,30.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,32.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,33.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,35.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,37.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,0.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,0.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,0.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,0.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,23.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,24.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,25.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,25.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,25.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,25.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,27.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,30.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,31.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,36.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,33.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,2.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,2.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,2.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,2.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,3.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,3.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,4.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,2.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,2.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,2.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,2.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,23.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,23.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,22.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,22.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,22.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,22.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,22.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,23.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,21
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,20.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,23
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,25.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,26.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,27.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,30.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,31.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,32.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,34.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,32.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,36.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,9.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,9.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,9.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,14.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,13.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,13.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,13.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,14.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,15.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,26.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,26.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,1.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,1.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,1.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,1.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,1.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,1.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,1.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,33.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,34.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,33.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,36.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,36.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,38.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,0.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,0.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,0.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,0.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,0.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,0.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,1.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,1.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,0.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,4.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,4.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,4.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,4.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,5.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,5.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,5.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,6.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,7.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,7.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,21.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,23.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,23.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,23.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,24
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,24.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,24.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,24.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,24.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,24.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,24.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,10.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,10.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,10.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,11.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,11.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,12.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,12.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,13.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,13.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,13.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,38.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,37.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,36.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,35.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,34
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,33.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,33.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,34.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,30.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,21.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,24.1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,22
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,25.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,24.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,23.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,18.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,20.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,23.6
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,14.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,43.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,41.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,40.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,39.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,38.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,38
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,37.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,38.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,39.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,39.8
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,16
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,15.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,16.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,20.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,22.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,24
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,25
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,29.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,30.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,32.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,28
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,28.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,28.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,35.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,34.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,34.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,33.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,33.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,33.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,33.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,32
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,5.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,2.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,4.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,4.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,4.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,4.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,4.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,4.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,4.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,5.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,4.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,4.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,6.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,7.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,7.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,7.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,7.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,7.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,8.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,8.6
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,135.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,139
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,133.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,154.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,156.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,170.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,82.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,87.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,94.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,100.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,107.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,116.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,123.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,131.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,138.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,135.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,26.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,25.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,25.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,25.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,25.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,24.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,24.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,24.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,24.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,24.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,22.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,14.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,14.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,14.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,14
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,13.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,12.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,13
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,13.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,13
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,13.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,11.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,28.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,25.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,24.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,24.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,24.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,19.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,18.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,18.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,18.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,21.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,121
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,123.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,128.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,131.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,135.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,142.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,147.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,161.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,173.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,186.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,197
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,6.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,6.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,6.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,6.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,6.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,6.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,39.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,38.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,38.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,39.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,39.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,38.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,39.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,41.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,44.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,44.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,47
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,7.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,7.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,8.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,8.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,9.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,9.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,9.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,9.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,14.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,14.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,14.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,14.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,14
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,13.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,16.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,18.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,17.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,17.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,20.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,20.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,20.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,21
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,21.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,23.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,24.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,24.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,28.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,221.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,221.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,220
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,221.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,219.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,220.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,223.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,224.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,222.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,221
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,221.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,10.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,11
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,10.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,11.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,12.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,12.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,13.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,13.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,12.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,13.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,57.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,58.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,57.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,58.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,57.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,58.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,56
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,58.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,56.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,61.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,34.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,34.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,34.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,34.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,33.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,33.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,34.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,33.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,31
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,31.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,31.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,57
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,57.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,53
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,54.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,52.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,54.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,5.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,5.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,5.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,5.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,4.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,4.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,4.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,19.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,19.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,20.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,21.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,22.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,22.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,20.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,20.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,24.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,26.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,6.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,7.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,7.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,7.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,6.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,6.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,6.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,6.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,6.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,52.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,51.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,50.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,49.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,48.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,47.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,47.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,46.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,45.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,45.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,44.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,4.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,5.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,4.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,4.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,4.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,3.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,3.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,3.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,3.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,3.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,82.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,85.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,86.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,86.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,86.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,88.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,89
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,89.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,88.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,88.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,20.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,11.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,11.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,11.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,12.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,12.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,13.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,15.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,15.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,17.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,46.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,45.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,47
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,48.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,50.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,53
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,55.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,58.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,61.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,62.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,70.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,81.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,81.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,82.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,84.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,84
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,84.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,86.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,85.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,87.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,93.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,13.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,12.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,11.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,11.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,10.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,10.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,9.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,9.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,9.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,9.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,13.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,12.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,12.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,12.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,11.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,12.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,11.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,9.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,8.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,11
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,20.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,21
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,21.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,22.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,23
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,23.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,24.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,23.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,24.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,25.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,10.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,11.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,13
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,14.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,16
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,17.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,20.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,21.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,21.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,18.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,1.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,1.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,1.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,1.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,1.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,18.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,17.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,17.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,18.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,17.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,16.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,17.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,18.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,19.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,20.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,1.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,1.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,1.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,1.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,0.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,60.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,65.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,69.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,73.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,74.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,75.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,79.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,78.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,81.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,84.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,18.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,17.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,16.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,21.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,20.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,21.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,22.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,23.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,23.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,24.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,8.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,8.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,9.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,8.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,7.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,7.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,5.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,8.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,10.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,11.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,8.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,10.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,13.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,13.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,11.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,9.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,7.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,7.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,7.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,6.8
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,143.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,149.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,155.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,289
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,288
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,290
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,297.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,299.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,305.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,301.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,23
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,23.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,23.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,25.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,26.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,28.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,31.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,34.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,36.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,45.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,8.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,8.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,7.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,7.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,7.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,7.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,6.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,3.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,3.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,3.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,4.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,3.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,3.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,4.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,140.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,276.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,228.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,215.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,173.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,161.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,231
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,281.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,246.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,284.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,179.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,5.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,4.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,4.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,4.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,4.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,4.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,4.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,4.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,1.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,1.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,1.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,1.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,1.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,9.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,9.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,8.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,8.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,8.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,8.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,7.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,7.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,7.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,8.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,162.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,173.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,175.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,178.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,179.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,182.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,184.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,186.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,188.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,190.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,191
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,45.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,47.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,53.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,50.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,51.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,57.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,58.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,57.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,56.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,61.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,62.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,13.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,13.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,14.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,14.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,14.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,14.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,15.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,15.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,14.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,14.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,3.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,2.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,2.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,2.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,2.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,1.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,5.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,5.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,5.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,6.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,6.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,6.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,12.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,12.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,12.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,13
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,13.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,14.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,16.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,18.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,18.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,23.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,13.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,13.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,13.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,15.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,16.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,16.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,15.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,14.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,15.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,19.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,25.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,23.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,22.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,22.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,20.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,20.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,20.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,20.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,22.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,25.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,57.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,56.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,54.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,52.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,51.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,51.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,51.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,50.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,50.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,0.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,0.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,0.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,1.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,12.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,13.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,12.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,12.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,11.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,11.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,12.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,11.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,11.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,11.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,11.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,11.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,11.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,11.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,11.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,12.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,12.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,12.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,12
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,12.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,9.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,8.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,8.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,8.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,8.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,8.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,8.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,8.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,8.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,8.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,19.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,19.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,18.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,18.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,18.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,18.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,19
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,19.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,19.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,19.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,19.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,104
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,110.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,117
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,124.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,125.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,126.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,128.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,128.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,128.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,126.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,65.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,64.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,65.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,64.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,65
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,61.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,60.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,59
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,58.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,59.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,1.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,0.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,0.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,116.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,116.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,117.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,113.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,107.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,104.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,104.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,103.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,99.4
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,11.1
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,10.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,58.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,57.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,56
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,55.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,53.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,53.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,53.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,54
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,53.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,52.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,52.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,24.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,24.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,25.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,26.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,27.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,29.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,30.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,34.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,36.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,40.5
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,2.4
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,2.3
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,2.3
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,1.7
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,1.5
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,1
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,1.2
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,1.4
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,1.6
MEX,Mexico,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,1.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,4.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,4.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,4.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,4.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,3.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,3.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,3.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,54.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,56
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,58.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,63.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,67.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,70
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,79.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,88.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,80.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,89.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,22.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,24.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,25.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,24.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,36.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,35.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,35.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,34.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,40.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,41.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,42.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,44.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,46.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,49.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,51.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,53.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,55.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,57.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,61.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,65.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,10.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,11.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,12.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,13.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,15
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,16.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,17.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,19.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,21.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,24.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,26.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,16
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,14.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,13.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,13.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,13.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,13.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,12.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,9.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,10.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,0.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,0.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,0.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,0.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,1.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,40.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,41.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,43.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,44.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,44.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,44.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,44.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,44.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,44.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,42.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,43.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,6.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,6.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,6.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,6.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,7.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,7.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,7.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,8.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,7.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,7.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,47.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,51.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,53.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,55.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,52
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,51.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,54.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,48.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,53.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,55.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,1.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,52.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,51.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,50.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,49.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,48.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,47.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,47.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,45.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,44.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,43
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,4.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,2.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,2.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,1.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,1.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,1.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,1.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,1.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,95
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,101
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,103.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,104.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,105.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,106.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,106.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,106.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,109
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,109.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,18.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,18.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,17.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,17.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,16.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,17.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,18
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,20
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,19.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,19
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,10.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,9.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,10
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,10.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,10.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,10.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,10.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,10.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,11.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,10.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,26.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,26.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,26
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,25.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,25.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,25.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,25.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,25.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,26
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,26.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,23.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,22.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,23.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,25.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,25.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,27.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,32.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,32.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,32.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,32
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,2.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,2.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,2.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,2.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,2.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,2.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,2.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,2.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,24.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,24.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,23.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,22.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,22.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,21.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,21.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,21.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,19.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,21.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,51.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,51.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,53
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,54.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,55.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,57
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,58.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,62
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,67
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,73.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,93.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,3.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,3.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,3.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,3.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,3.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,4.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,4.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,4.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,5.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,54.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,54.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,55
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,55.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,56.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,59.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,61.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,64.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,66.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,68.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,68
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,125.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,132.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,141.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,141.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,148.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,157.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,167.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,181.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,195.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,211.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,229.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,69.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,68.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,68.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,67.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,70.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,74.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,78.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,81.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,85.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,10.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,9.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,10.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,10.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,10.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,10.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,22.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,24.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,24
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,4.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,5.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,5.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,6.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,5.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,5.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,5.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,5.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,5.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,6.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,42.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,41.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,40.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,40.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,40.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,40.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,40.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,41.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,39.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,38.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,37.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,22.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,24.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,23.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,21.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,18.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,19.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,13.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,14.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,16.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2023,16
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,2.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,2.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,2.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,2.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,3.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,3.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,3.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,18.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,18.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,18.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,18.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,18.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,18.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,17.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,16.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,16.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,15.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,35.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,35.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,34.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,33.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,31.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,31.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,32.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,30.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,30.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,31
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,30.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,17.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,18.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,20
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,20.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,21.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,23.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,24.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,25.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,27.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,31.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,9.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,8.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,8.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,7.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,7.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,7.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,7.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,7.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,7.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,8.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,9.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,8.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,8.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,8.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,8.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,8.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,8.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,8.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,85.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,90.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,93.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,94.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,88.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,85.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,84.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,83.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,83.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,83.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,14.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,13.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,13.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,13.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,12.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,12.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,12.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,10.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,10.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,11.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2023,11.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,8.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,8.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,8.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,8.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,8.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,8.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,8.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,8.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,8.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,1.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,1.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,1.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,1.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,1.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,1.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,30.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,31.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,33.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,34.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,36.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,38.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,39.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,38.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,40.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,43.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,42.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,9.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,9.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,9.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,10.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,10.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,10.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,10.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,9.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,9.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,10.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,41.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,42.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,44.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,46.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,47.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,48
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,48.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,56.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,60.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,63.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,77.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,21.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,20.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,20.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,19.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,19.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,18.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,18.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,16.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,16.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,16.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,23.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,25.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,28.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,33.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,39.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,46.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,52.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,58.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,62.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,68.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,0.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,0.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,0.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,0.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,0.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,0.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,143.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,141.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,140
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,143.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,144.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,148.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,151.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,152.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,156.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,166.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,163.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,87.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,87
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,89.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,90.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,91.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,92.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,94.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,97.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,100.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,98.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,111
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,3.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,3.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,3.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,4.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,4.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,4.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,4.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,4.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,4.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,5.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,19.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,21.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,23.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,27.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,29.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,30.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,33.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,35.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,38.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,44.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,19.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,19.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,18.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,17.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,15.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,15.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,14.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,11.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,11.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,12.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,0.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,0.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,6.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,6.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,6.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,6.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,5.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,5.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,5.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,5.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,5.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,5.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,33.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,34
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,33.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,34.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,32.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,31.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,31.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,31.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,29.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,28.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,26.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,79.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,81.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,83.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,87.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,87.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,85
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,89.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,84.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,89.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,90.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,9.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,10.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,11.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,12.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,13.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,14.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,17.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,20.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,19.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,16.9
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,4.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,3.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,3.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,3.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,3.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,3.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,3.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,3.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,5.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,5.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,5.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,6.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,6.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,5.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,5.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,5.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,4.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,4.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,13.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,12.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,13.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,12.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,14
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,13.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,13.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,11.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,11.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,15
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,20.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,22.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,23.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,25.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,30.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,33.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,41.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,43.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,45.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,47.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,16.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,17.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,18.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,20.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,23
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,25.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,27.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,31.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,33
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,39.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,35.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,14.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,13.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,13.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,12.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,12.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,13
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,13
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,14
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,14.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,14.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,16.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,16
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,15.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,17.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,17.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,21.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,26.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,34.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,43.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,115.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,111.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,115.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,109.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,107.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,104.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,102.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,101.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,103.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,94.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,54.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,53.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,52.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,54.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,58.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,60.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,66
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,70.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,67.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,67.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,71.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,58.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,61.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,62.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,62.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,62.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,62.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,63
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,63.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,65.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,72.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,69.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,57.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,62.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,67.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,69.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,71.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,76
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,79.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,95
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,95.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,96.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,98
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,85.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,88.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,89.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,92.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,91.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,95.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,99.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,101.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,105.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,3.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,4.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,4.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,3.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,4.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,3.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,4.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,3.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,5.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,5.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,14.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,16.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,20
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,22.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,26.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,29.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,27.3
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,30.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,20.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,37.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,9.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,10
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,9.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,9.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,8.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,8.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,8.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,2.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,1.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,1.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,2.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,2.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,2.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,2.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,2.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,3.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,7.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,8.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,8.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,9.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,10.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,11.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,12.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,13
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,10.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,13.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,71.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,70.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,68.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,68
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,65.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,63.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,62.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,62.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,60.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,60.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,2.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,2.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,2.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,2.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,2.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,1.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,2.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,2.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,2.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,2.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,7.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,8.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,8.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,8.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,8.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,8.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,8.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,8.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,8.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,16.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,16.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,17.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,19.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,20.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,23.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,26.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,29.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,32.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,38.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,6.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,6.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,6.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,7.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,7.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,7.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,7.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,7.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,7.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,7.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,77.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,76.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,69.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,72.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,74.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,75.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,77
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,79.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,76.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,75.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,78.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,39.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,35
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,34.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,34.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,34.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,34.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,33.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,33.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,32.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,29.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,45.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,47.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,49
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,47.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,48.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,47.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,49.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,48
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,46.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,47.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,77.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,79.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,82.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,87
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,87.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,87.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,88.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,87.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,87.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,85.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,88.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,2.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,2.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,2.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,1.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,1.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,1.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,1.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,1.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,2.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,263.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,260.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,258.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,255.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,250.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,247.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,243.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,239.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,234.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,232.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,31.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,34.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,38.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,44.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,49.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,53.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,57.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,66
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,74.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,88.1
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,38.5
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,34.2
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,35.1
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,31.7
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,31.6
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,35.5
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,51.8
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,49.6
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,48.2
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,52.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,2.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,2.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,47.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,45.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,45
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,45.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,44.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,44.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,45.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,44.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,43.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,42.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,7.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,6.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,6.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,6.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,6.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,6.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,6.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,5.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,6.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,6.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,7.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,7.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,8.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,8.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,7.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,7.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,6.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,6.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,2.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,2.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,2.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,2.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,2.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,2.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,2.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,2.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,2.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,2.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,14.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,12.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,12.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,12.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,10.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,10.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,9.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,14
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,12.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,17.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,58.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,58.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,62
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,65.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,67.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,70.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,72.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,73.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,79.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,83.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,80
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,76.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,77
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,76.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,75.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,76.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,78.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,80.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,84.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,88.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,92.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,1.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,1.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,79.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,77.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,75.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,74.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,73.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,70.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,70.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,67.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,64.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,63.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,61.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,78
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,77.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,76.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,75.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,73.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,71.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,70.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,70.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,68.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,65.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,41.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,39.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,40.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,40.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,35.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,31
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,31.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,24.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,27
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,34.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,24.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,23
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,21.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,20
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,18.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,17.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,16.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,15.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,14.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,32.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,37.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,41.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,46.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,50
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,54
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,59.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,62.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,67.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,76.5
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,7.9
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,8.1
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,8.5
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,9
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,9.3
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,8.6
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,8.7
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,9.1
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,8.8
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,9.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,7.3
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,7.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,1.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,0.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,0.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,1.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,0.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,0.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,25.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,25.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,25.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,25.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,24.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,22.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,20.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,21.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,22.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,21.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,63.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,66.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,68.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,69.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,71.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,72.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,72.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,75.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,70.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,71.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,70
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,23.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,24.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,25.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,26.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,28.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,29.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,29.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,30.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,31.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,32.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,28.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,7.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,6.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,6.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,6.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,6.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,6.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,9.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,9.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,9.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,22.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,24.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,25.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,26.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,28.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,28.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,29.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,29.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,29.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,30.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,32.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,27.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,26.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,27.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,26.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,26.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,27.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,26.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,25.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,25.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,3.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,3.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,2.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,2.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,2.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,3.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,3.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,4.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,4.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,0.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,29
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,32.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,37.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,38
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,40.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,43.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,44.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,48.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,44.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,45
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,97
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,94
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,90.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,87.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,83.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,81.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,83.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,83.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,80.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,81.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,80
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,11.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,11
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,11.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,11.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,10.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,9.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,9.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,8.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,7.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,5.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,5.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,5.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,5.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,5.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,5.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,5.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,5.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,5.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,17.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,15.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,15.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,16.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,16.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,16.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,16.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,14.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,14.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,18.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,24.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,25.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,27.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,29.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,32.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,31.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,35.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,36.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,37.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,40.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,6.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,6.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,6.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,7.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,7.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,6.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,7.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,7.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,7.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,7.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,29.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,25.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,24.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,23.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,21.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,19.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,21.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,21
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,20.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,22.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,5.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,6.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,5.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,5.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,6.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,6.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,7.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,7.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,6.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,12
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,13.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,12.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,22.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,22.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,24.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,28.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,21.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,20
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,21.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,2.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,2.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,2.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,3.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,36.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,36.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,35.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,33.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,32.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,31.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,30.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,19.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,16.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,20.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,23.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,24.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,27.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,29.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,29.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,30.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,31.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,31.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,35.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,50.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,52.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,53.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,55
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,55.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,55.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,57.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,61.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,58.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,60.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,60.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,0.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,1.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,15
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,15.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,15.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,14.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,14.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,14.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,13.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,13.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,14.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,14.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,6.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,5.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,5.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,5.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,5.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,5.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,5.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,5.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,6.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,115.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,112.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,113.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,110.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,110.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,107.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,108.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,98.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,97.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,100.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,2.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,2.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,2.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,2.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,2.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,2.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,2.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,4.7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.9
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,4.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,4.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,3.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,3.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,3.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,2.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,2.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,71
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,74.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,77.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,82.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,87.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,93.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,101.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,103.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,93.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,96.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,57.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,54.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,50.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,57.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,54.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,50.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,50.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,47
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,44.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,36.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,2.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,1.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,2.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,1.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,28.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,16.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,27.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,30
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,23.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,20.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,32.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,38.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,52
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,30.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,54.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,2.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,2.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,2.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,2.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,2.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,3.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,3.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,3.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,3.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,3.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,41.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,41.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,41
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,40.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,37.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,33.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,32.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,29.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,25
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,22.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,78
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,82.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,87.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,91.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,96.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,100.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,104.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,109.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,109.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,110.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,95.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,3.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,9.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,8.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,9.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,8.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,8.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,9.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,9.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,12.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,14.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,43.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,44.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,43.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,43.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,41.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,38.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,37.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,37.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,36.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,34.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,4.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,5.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,5.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,5.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,4.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,5.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,5.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,5.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,4.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,6.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,3.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,3.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,3.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,4.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,4.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,4.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,4.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,4.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,4.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,4.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,17.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,18
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,18.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,14.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,14.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,14.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,14.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,15.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,10.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,10.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,13.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,13.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,13.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,14.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,14.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,15.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,16
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,16
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,17.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,18.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,38.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,38.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,38.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,38.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,38.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,38.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,39.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,38.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,37.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,36.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,36.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,15.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,18.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,20.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,23
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,24.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,25.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,26.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,27.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,28.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,35.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,14.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,9.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,11.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,10.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,10.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,11.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,12.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,13
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,13.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,14.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,6.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,7.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,7.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,7.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,8.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,13.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,14.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,13.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,13.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,15.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,11
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,9.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,9.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,9.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,10.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,12.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,9.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,11.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,10.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,18.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,19.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,19.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,21.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,22.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,24.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,27.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,30.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,33.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,39.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,2.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,2.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,2.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,4.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,5.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,5.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,5.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,6.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,5.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,5.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,6.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,32.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,35.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,34.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,36.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,36.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,37.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,38.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,36.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,38.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,38.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,44.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,45
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,46.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,35.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,36.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,37.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,37.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,38.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,40
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,40.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,58.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,58.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,58.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,58.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,57.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,58
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,57.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,54.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,55
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,57.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,17
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,18.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,19.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,22.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,24.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,26.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,29.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,32.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,33.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,38.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,65.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,64.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,60.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,61.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,64.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,65.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,66.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,70.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,69.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,76.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,20.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,20.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,20.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,19.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,19.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,18.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,18.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,16.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,16.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,17.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,84
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,86.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,91.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,98.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,102.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,106.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,109
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,114.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,117.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,114.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,121.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,45.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,45.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,44.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,44.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,44.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,45
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,47.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,47.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,47.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,48.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,47.9
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,2.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,42.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,43.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,43.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,44.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,43.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,44.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,44.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,43.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,43.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,44.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,23.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,22.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,21.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,19.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,19.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,18.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,18.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,16.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,17.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,19.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,18.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,54.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,54.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,55.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,57.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,57.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,57.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,60.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,62.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,63.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,64
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,3.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,3.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,3.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,3.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,3.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,152.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,152.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,152
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,97.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,98.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,93.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,95
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,98.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,100.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,107.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,11.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,11.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,11.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,11.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,12.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,12.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,12.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,12.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,11
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,9.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,9.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,8.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,8.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,8.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,8.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,9.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,9.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,9.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,10.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,1.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,1.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,1.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,2.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,2.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,1.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,3.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,3.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,3.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,3.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,3.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,3.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,3.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,3.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,3.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,20.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,23.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,24.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,15.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,14.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,14.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,14.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,11.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,13.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,15.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,9.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,9.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,9.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,9.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,9.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,10.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,10.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,12.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,12.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,8.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,10.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,9.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,10.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,10.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,10
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,10
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,11.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,13.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,14.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,1.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,1.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,1.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,1.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,33.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,33
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,33.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,33.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,32.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,33
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,31.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,29.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,28.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,2.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,2.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,2.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,2.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,2.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,3.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,3.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,4.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,4.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,3.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,3.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,3.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,3.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,42.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,46.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,49
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,45.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,46.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,49.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,50.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,51.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,52.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,60
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,38.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,37
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,35.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,33.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,32
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,31.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,30.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,29.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,28.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,27.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,26.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,25
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,26.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,28.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,29.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,31.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,32.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,33
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,36.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,35.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,39.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,27.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,26
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,25.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,23.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,22.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,19.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,18
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,19
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,18.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,18.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,4.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,4.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,4.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,19.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,17.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,16
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,17
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,16.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,17.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,18.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,19.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,19.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,17.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,0.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,0.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,0.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,0.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,0.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,0.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,0.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,0.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,101.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,96.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,101.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,103.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,103.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,103.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,105.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,106.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,110.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,109.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,110.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,47.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,45.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,43.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,41.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,45.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,46.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,48
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,52.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,54.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,57.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,36.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,38.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,40.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,41
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,43.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,44.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,44.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,48.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,52.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,55.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,68.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,68.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,66.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,45.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,35.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,33.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,32.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,30.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,29.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,29.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,28.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,30.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,30.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,31.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,31.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,32.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,32.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,34.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,35.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,35.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,34.7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,9
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,7.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,1.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,1.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,1.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,1.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,38.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,38.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,40.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,44.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,48.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,51.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,56.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,60.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,62
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,65.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,1.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,0.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,0.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,2.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,1.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,0.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,1.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,1.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,2.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,2.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,2.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,1.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,83.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,85.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,84.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,79.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,77.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,77.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,79.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,81
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,84.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,83.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,81.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,51.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,53.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,54.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,56.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,59.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,60.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,63.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,65.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,68.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,70
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,66.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,71.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,72.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,75.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,76.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,78.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,79.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,81.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,84.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,89.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,92.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,12.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,12.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,12.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,11.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,11.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,10.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,9.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,8.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,9.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,11.6
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,13.9
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,14
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,14.6
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,14.5
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,13.7
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,13.3
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,13.1
JPN,Japan,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,10.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,13.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,13.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,14.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,14.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,14.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,14.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,15.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,15.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,15
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,13.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,8.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,9.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,9.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,9.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,9.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,10.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,11.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,12.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,13.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,41.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,43.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,46.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,36.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,42
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,40.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,52
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,67
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,90.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,94.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,95.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,23.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,22.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,22.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,24.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,26.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,21.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,21.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,23.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,25
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,28.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,5.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,6.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,6.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,6.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,6.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,7.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,7.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,7.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,7.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,39.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,39.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,37.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,36.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,35
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,33.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,32.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,31.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,29.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,28
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,22.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,23.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,22.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,21.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,21.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,20.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,20.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,19.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,19.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,19.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,3.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,3.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,3.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,3.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,27.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,28.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,29.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,30.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,30.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,30.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,30.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,29.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,29.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,30.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,53.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,56
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,53.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,54.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,53
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,52.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,54.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,55.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,53.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,14.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,14.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,15.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,14.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,12.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,13.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,13.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,12.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,12.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,13.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,47
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,47.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,47.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,48.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,48.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,49.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,49.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,48.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,48.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,49.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,47.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,39
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,39.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,39.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,39.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,40.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,41.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,42.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,43.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,44.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,45.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,47.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,83.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,83.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,82.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,83.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,83.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,85.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,88.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,91
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,93.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,101
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,27.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,25.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,23.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,24.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,24
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,25.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,28.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,31.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,32.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,6.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,7.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,8.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,9.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,9.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,10.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,11.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,12
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,11.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,11.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,75.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,75
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,75.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,76.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,77.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,75.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,76.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,77.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,78.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,81.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,3.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,3.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,25.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,26.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,26.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,28.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,26.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,24.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,25.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,27.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,28.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,32.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,10.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,10.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,9.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,9.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,9.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,9.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,9.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,9.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,8.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,9.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,1.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,1.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,1.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,1.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,1.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,1.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,2.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,2.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,4.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,7.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,53.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,55
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,56.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,58.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,59.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,61.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,63.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,63.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,66.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,68.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,1.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,1.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,1.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,1.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,1
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,12.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,42.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,44.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,47.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,45.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,47
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,52.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,55.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,60.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,63
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,69.7
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,12.9
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,12.1
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,13.9
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,11.9
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,13.1
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,11.8
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,19.7
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,19.7
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,21.5
JPN,Japan,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,25.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,195.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,198
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,199.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,209.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,206.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,205.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,205.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,207.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,203.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,207.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,0.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,2.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,2.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,73
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,76.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,79.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,84
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,87.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,94.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,103.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,113.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,125.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,135.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,67
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,73.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,68.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,268.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,165.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,179.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,137.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,131.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,142.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,148.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,6.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,6.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,6.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,8.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,7.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,6.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,6.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,6.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,5.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,14
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,13.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,12.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,12.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,12
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,12
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,11.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,8.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,8.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,10.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,18.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,18.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,17.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,17.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,16.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,16.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,16.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,16.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,16.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,16.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,15.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,4.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,4.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,4.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,4.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,72.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,72
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,74.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,75.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,76.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,74.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,77.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,64.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,71.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,78.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,6.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,6.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,6.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,7.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,7.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,7.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,7.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,6.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,6.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.9
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,12.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,10.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,78.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,78.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,78.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,75.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,72.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,67.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,66.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,64.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,62
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,7.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,7.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,10.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,7.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,8.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,9.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,23.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,36.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,31.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,34.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,60.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,182.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,180.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,178.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,193.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,195.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,200.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,205.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,210.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,214.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,216.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,215.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,16.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,16
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,14.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,14
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,13.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,12.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,12
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,12
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,11.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,11.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,11.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,10.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,9.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,8.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,8.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,8.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,9.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,10.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,10.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,11.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,9.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,4.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,4.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,4.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,4.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,4.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,5.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,5.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,6.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,6.7
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,0.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,8.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,9.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,9.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,10
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,9.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,9.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,10.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,9.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,9.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,9.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,1.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,63.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,62.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,73.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,42.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,52.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,54.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,52.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,79.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,81.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,69.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,55.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,95.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,97
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,99.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,95.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,97.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,93.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,83.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,84.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,88.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,104.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,8.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,10.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,12.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,13.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,15.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,14.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,18.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,22.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,25.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,28.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,1.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,1.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,1.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,1.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,1.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,2.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,2.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,2.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,17.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,17
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,17.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,18
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,18.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,18.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,16.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,19
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,19.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,19.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,32.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,34.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,35.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,40.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,45.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,49.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,52.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,52
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,57
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,52.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,42.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,43.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,43.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,44.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,44.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,44.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,44.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,44.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,44.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,44.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,35.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,35.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,34.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,33
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,31.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,31.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,34.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,40
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,40
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,40.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,65.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,71.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,73.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,75.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,77.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,80.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,83.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,86.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,92.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,98.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,101.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,11
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,11.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,10.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,12.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,10.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,12.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,12.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,12.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,14.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,16.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,1.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,1.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,1.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,1.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,1.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,1.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,4.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,1.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,1.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,1.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,1.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,1.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,1.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,52.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,52.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,46.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,54.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,50.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,54.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,56.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,52.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,57.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,48.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,22.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,23
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,21.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,22.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,23.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,23.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,24.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,25.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,27.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,25.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,3.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,3.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,4.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,4.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,5.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,1.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,1.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,1.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,1.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,1.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,3.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,23.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,22
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,22.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,22.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,22.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,23.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,21.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,19.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,21.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,13.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,13.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,12.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,13.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,12
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,11.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,10.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,8.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,8.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,9.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,17.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,16.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,16.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,15.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,16.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,17.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,18.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,20.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,21.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,0.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,65.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,70.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,75.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,76.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,76
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,76.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,78.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,80.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,79.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,92.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,46.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,48.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,50.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,51.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,52.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,52.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,53.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,54.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,57.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,57.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,10.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,10.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,10.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,10.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,10.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,10.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,11.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,11.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,11.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,11.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,12.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,13
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,12.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,13.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,15
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,15.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,15.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,14.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,15
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,14.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,5.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,5.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,4.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,4.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,4.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,4.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,4.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,4.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,7.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,7.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,7.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,8.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,9.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,9.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,10.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,10.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,10.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,49
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,52.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,55
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,57.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,59.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,61.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,64.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,65.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,69.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,73.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,4.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,5.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,5.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,5.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,5.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,6.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,6.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,6.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,6.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,14.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,14.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,15.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,15.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,14.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,14
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,13.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,14
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,14.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,19.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,25.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,22.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,20.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,21.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,22
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,22
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,23.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,23.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,24.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,26.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,2.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,1.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,1.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,1.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,1.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,1.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,1.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,1.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,1.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,1.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,1.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,35
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,37.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,37.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,38.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,38.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,39.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,40.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,41.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,41.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,42.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,42.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,3.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,5.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,6.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,7.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,7.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,8.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,6.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,7.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,8.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,8.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,7.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,7.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,6.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,6.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,6.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,6.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,7.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,7.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,6.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,23.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,30
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,18.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,17.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,17.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,17.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,16.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,14.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,14.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,15.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,16.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,5.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,5.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,5.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,4.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,4.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,5.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,6.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,6.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,7.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,10
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,21.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,21.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,21.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,23.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,23
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,22.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,23.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,25.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,26.8
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,28.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,4.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,4.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,5.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,5.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,4.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,4.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,4.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,4.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,4.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,66.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,68.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,69.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,71.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,73.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,75.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,78.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,80.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,85.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,91.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,92.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,4.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,3.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,2.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,2.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,70.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,73.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,76.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,79.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,80.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,80
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,82.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,83
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,85.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,87.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,87.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,6.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,6.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,7.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,7.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,7.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,8.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,7.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,9.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,6.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,6.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,7.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,6.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,6.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,6.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,5.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,5.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,4.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,19.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,18.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,15.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,16.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,15.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,15
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,14.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,13.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,12.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,13
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,1.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,1.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,1.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,1.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,2.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,2.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,2.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,2.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,2.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,2.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,4.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,4.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,4.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,4.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,4.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,3.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,3.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,4.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,0.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,0.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,0.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,121.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,121.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,124.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,127.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,128.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,133.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,133.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,136.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,138.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,136.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,147.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,14.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,9.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,9.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,9.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,9.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,8.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,8.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,9.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,9.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,1.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,1.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,1.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,1.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,1.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,1.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,1.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,1.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,37.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,37
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,35.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,33.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,33.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,31.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,31.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,33.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,31.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,30.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,30.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,2.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,2.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,2.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,2.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,2.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,2.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,2.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,2.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,3.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,7.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,7.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,8.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,9.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,9.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,10.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,9.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,9.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,9.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,12.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,12.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,12.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,14.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,14.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,14.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,14.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,14.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,15.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,18.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,38.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,30.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,23.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,20.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,18.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,17.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,17
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,17.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,17.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,17.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,57.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,57.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,57.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,56.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,57.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,57.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,57.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,60.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,63.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,66.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,3.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,3.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,3.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,3.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,3.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,3.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,3.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,3.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,111.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,116.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,120.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,124.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,129.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,133.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,136.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,137.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,140.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,144.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,37.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,39.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,43.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,47.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,49
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,54.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,62.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,68.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,74.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,89.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,3.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,3.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,3.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,3.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,3.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,3.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,4.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,4.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,11.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,11.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,11.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,14.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,15.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,16.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,51.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,54.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,52.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,53.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,55.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,55.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,56.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,59.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,58.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,17.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,17.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,17.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,18.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,19.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,20.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,20.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,23.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,26.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,28.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,27.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,27.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,27
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,27.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,28.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,28.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,29.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,34.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,39
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,37.8
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,7.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,64.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,67
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,68.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,68.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,68.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,67.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,68.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,69.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,68.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,73.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,70.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,13.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,12.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,12.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,12.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,12.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,12.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,12.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,12.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,12.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,13.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,29.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,29.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,28.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,29.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,30.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,33.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,35.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,39
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,41.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,34.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,47.9
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,3.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,47.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,48.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,48.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,49.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,50.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,51.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,52.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,53.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,53.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,54.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,55.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,17
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,18
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,20.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,17.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,18.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,21
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,23.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,27.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,31.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,34.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,7.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,7.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,7.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,7.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,7.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,8.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,8.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,7.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,11.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,12.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,13.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,13.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,13.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,13.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,13.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,14.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,13.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,14.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,22.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,18.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,17.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,18.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,19
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,18.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,19.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,20.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,21.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,26.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,25.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,25.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,24.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,23.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,23.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,22.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,21.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,21.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,20.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,4.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,4.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,4.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,4.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,4.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,4.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,4.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,4.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,4.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,4.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,33.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,34.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,32.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,32.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,31.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,28.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,28.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,29.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,31.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,33
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,7.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,7.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,7.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,8.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,8.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,9.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,9.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,10.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,9.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,9.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,46
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,46.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,46.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,46.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,47.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,46.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,47.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,49.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,49.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,52
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,33
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,32.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,31.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,33.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,32.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,33.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,92.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,95
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,94.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,97.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,91.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,65.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,62
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,61.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,56.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,58.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,62.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,56.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,54.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,52.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,50.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,49.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,48.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,49.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,45.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,43.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,37.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,96.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,100.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,104.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,106.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,109.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,112.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,115.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,122.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,127.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,130.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,2.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,2.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,49.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,49.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,47.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,46.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,45.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,44.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,42.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,42.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,47
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,46.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,1.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,1.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,1.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,1.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,1.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,9.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,8.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,7.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,6.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,6.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,5.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,5.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,4.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,4.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,4.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,2.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,2.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,2.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,2.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,2.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,2.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,2.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,2.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,2.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,14.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,13.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,12.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,11.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,11.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,10.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,10.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,10.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,9.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,9.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,27.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,27.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,24.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,23.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,22.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,21.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,21.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,21.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,20.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,17
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,21.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,18.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,25.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,27.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,23.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,21.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,19.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,19.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,28.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,26.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,24.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,36.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,40.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,41.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,43.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,35.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,33.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,31
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,29.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,29
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,30.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,30.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,11.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,10.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,11
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,10.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,10.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,10.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,10.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,7.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,7.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,10.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,3.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,3.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,4.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,4.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,5.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,5.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,5.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,6.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,7.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,7.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,7.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,107.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,104.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,102.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,99.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,96.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,95.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,96.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,85.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,75.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,16.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,17.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,17.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,18
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,18.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,19.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,20.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,20.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,20.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,21.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,30.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,31.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,31.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,30.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,29
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,29.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,26.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,21
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,19.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,25.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,3.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,3.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,3.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,4.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,5.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,5.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,6.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,5.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,5.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,7.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,5.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,5.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,5.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,5.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,5.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,6.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,6.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,6.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,6.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,25.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,27.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,22.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,22.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,21.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,20.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,20.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,13
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,13.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,14.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2023,19.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,61.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,60.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,64.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,86.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,95.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,96.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,98.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,98.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,101.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,101.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,93.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,29.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,31
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,33.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,33.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,34.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,34.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,34.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,28.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,23.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,32.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,28.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,27.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,27.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,26
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,24
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,22.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,21.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,20.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,21.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,20.6
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,3.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,24.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,24.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,25
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,25.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,25.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,26.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,27.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,27.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,34.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,36.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,6.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,5.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,4.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,4.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,4.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,4.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,4.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,4.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,4.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,5.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,3.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,3.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,3.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,3.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,3.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,3.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,3.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,3.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,3.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,2.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,2.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,2.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,2.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,7.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,6.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,6.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,6.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,6.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,6.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,7.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,8.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,7.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,6.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,6.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,5.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,5.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,5.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,6.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,8.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,9.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,9.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,11.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,26.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,28.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,29.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,31
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,32.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,33.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,34.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,37.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,35.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,36.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,36.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,25.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,17.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,14.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,13.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,13.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,13.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,13.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,13.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,14.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,15.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,71.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,72.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,74.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,76.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,75.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,78.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,79.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,81
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,83.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,2.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,2.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,2.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,1.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,1.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,2.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,2.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,2.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,4.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,4.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,4.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,2.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,2.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,5.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,5.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,5.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,5.1
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,4.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,3.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,3.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,3.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,5.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,6.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,7.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,8.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,8.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,9.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,10.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,11.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,12.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,13.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,8.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,5.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,5.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,4.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,5.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,6.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,7.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,37.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,37.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,36.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,35.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,35.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,33
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,32
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,33.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,29.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,32.2
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,4.5
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,2.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,11.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,10.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,10.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,10.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,10.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,11.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,11
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,11.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,11.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,10.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,7.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,7.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,7.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,7.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,6.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,6.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,6.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,5.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,5.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,187.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,193.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,196.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,204.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,223.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,242.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,245.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,244.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,243
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,275.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,109.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,112.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,115.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,115
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,115
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,116.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,116
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,117.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,118.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,131
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,12.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,10.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,13.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,13.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,12.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,15.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,17.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,17.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,23.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,20.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,2.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,2.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,2.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,2.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,2.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,4.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,4.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,4.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,4.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,4.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,4.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,3.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,2.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,0.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,57.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,57.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,57.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,58.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,58
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,58.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,61.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,62.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,63.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,65.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,67.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,2.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,2.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,2.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,3.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,3.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,3.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,3.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,3.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,3.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,4.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,4.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,4.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,5.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,5.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,62
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,64.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,65.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,65.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,63.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,65.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,66.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,66.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,68.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,70.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,4.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,4.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,4.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,4.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,4.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,3.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,3.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,3.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,1.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,27.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,26.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,26.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,24.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,19.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,20
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,23.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,1.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,1.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,1.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,1.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,1.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,1.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,8.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,8.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,8.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,8.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,7.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,7.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,7.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,7.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,12.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,13.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,13.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,11.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,11.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,12.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,12.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,12.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,14.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,26.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,5.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,4.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,4.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,5.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,5.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,5.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,6.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,6.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,6.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,6.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,8.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,9.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,9.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,10.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,11.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,12
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,13.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,16
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,15.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,16.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,17.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,62.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,63.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,64.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,67.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,66.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,69.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,77.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,79.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,75.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,5.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,5.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,5.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,5.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,5.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,5.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,5.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,5.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,5.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,6.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,6.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,6.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,6.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,6.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,6.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,7.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,7.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,8.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,57.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,57.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,62.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,72.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,74.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,75.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,83.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,88.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,90.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,95.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,80.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,81.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,82.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,83.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,84
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,87
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,92.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,96.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,98.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,100.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,16.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,17.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,18.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,15.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,14.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,16.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,23.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,24.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,30.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,36.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2023,35.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,22.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,20.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,19.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,18.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,16.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,17
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,17.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,18.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,20.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,21.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,17
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,16.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,17
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,17.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,17
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,17.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,19
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,20.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,22.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,25.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,8.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,9.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,9.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,9.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,10.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,10.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,12
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,12.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,11.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,10.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,9.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,9.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,9.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,9.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,10.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,10
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,10.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,10.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,10
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,11.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,101.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,104.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,106.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,109.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,112.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,114.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,115.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,112.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,115.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,112.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,13.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,13.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,13.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,13.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,12.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,12.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,12
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,11.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,11
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,11.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,13.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,13.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,16.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,16
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,15.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,15.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,19.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,36.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,31.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,41.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,49.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,24.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,25.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,23.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,23
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,22.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,22.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,23.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,21.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,24.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,20.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,26.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,4.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,4.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,4.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,4.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,2.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,2.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,2.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,3.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,3.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,3.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,4.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,4.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,5.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,53.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,61.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,61.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,67.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,71.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,79.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,89.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,97.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,110.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,42.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,46.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,48.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,73.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,73.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,73.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,74
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,76.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,79.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,79
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,77.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,135.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,132.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,129.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,126.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,125.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,124.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,123.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,126.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,128.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,129.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,17.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,18.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,15.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,21
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,19.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,18.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,17.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,16
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,15.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,15.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,14.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,217.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,220.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,214.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,213.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,220.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,218.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,231.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,239.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,231.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,235
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,41.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,46
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,43.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,62.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,66.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,69
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,75.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,73.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,89.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,86.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,2.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,2.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,2.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,2.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,2.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,2.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,2.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,3.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,2.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,28.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,27.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,27.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,27.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,26.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,25.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,27.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,28.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,27.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,30
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,8.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,7.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,7.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,9.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,10
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,9.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,8.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,9.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,9.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,9.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,9.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,10.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,11.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,11.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,10.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,10.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,8.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,8.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,9.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,35.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,37.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,32.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,41
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,43.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,46.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,48.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,50.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,51.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,51.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,59.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,78.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,79
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,89.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,85.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,81.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,0
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,3.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,3.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,3.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,3.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,3.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,4.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,4.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,5.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,81.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,80.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,80.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,79.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,79.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,74.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,75.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,77.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,76.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,79.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,80
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,22.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,17.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,16.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,17.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,17.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,17.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,18
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,15.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,14.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,16.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,2.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,2.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,2.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,2.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,2.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,2.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,3.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,3.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,14
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,13.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,13.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,13.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,13.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,13.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,13.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,14.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,13.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,13.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,3.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,3.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,3.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,3.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,3.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,3.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,3.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,4.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,4.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,4.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,20.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,21.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,24
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,26.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,30
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,34.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,37.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,44.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,50.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,58.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,57.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,60.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,54.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,54.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,54.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,56.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,57.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,60.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,61.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,49.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,59.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,1.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,1.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,1.1
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,64
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,64.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,65.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,64.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,64.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,64
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,65.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,64.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,60
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,72.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,74.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,77.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,79
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,78.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,79.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,81.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,83.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,86.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,88.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,3.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,3.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,3.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,3.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,2.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,2.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,2.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,2.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,2.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,9.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,9.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,10.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,10.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,11.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,10.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,11.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,10.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,10.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,11.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,81.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,82.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,81.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,92
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,96
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,100.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,10.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,10.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,7.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,7.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,7.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,7.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,6.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,7.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,6.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,43.7
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,42.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,40.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,45.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,43.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,44.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,84.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,87.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,92.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,95
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,96.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,98.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,102.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,105.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,108.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,114.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,117.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,2.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,2.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,2.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,2.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,0.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,1.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,0.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,0.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,1.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,0.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,0.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,32.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,33.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,33.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,34.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,34.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,36.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,38
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,39.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,39.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,40
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,39.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,6.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,7.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,7.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,7.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,8.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,9.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,9.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,10.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,4.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,4.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,5.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,6.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,6.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,6.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,6.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,7.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,7.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,7.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,65.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,71.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,71.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,73.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,75
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,74.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,77.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,80.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,76.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,78.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,2.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,2.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,2.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,2.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,2.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,2.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,3.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,3.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,3.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,3.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,30.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,30.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,29.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,29.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,29.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,29
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,28.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,28.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,28.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,27.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,53.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,56.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,59.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,62.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,65.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,67.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,70.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,72
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,74.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,76.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,77.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,4.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,4.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,4.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,3.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,3.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,3.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,3.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,2.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,2.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,2.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,18.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,15.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,14.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,14.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,14.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,13.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,12.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,13
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,12.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,13.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,98.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,100.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,94.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,103.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,110.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,111.7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,2.6
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,2.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,15.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,16
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,13.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,12.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,11.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,11.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,11.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,11.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,11
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,10.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,46
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,46.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,45.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,45.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,45.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,44.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,46.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,46.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,49.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,51.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,53.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,1.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,1.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,1.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,1.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,4.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,4.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,3.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,28.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,29.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,29.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,26.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,26.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,23.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,26.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,24.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,25
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,24.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,6.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,6.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,6.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,6.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,7.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,7.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,7.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,133
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,134.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,135.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,137.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,141.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,143.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,142.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,141.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,142
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,141.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,21.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,23.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,24.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,27.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,28.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,31.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,34.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,37
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,40.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,44.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,47.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,6.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,5.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,6.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,6.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,6.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,6.9
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,6.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,6.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,5.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,6.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,7.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,7.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,7.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,8.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,10.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,8.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,10.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,11.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,10.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,9.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,9.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,8.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,7.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,7.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,6.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,6.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,5.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,3.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,3.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,3.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,4.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,25.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,24.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,25.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,25.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,24.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,25.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,25.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,20.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,21.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,24.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,5.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,5.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,4.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,5.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,5.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,5.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,5.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,5.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,5.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,4.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,7.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,7.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,6.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,6.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,6.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,7.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,6.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,7.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,3.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,3.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,3.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,3.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,3.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,3.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,3.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,12.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,12.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,12.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,12.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,13.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,14.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,14.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,15.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,15.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,15.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,60.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,58.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,55.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,53
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,50.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,48.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,47.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,45.9
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,44.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,42.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,174.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,175.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,177.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,179.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,180.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,188.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,201
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,212.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,219.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,226.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,240.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,3.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,3.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,3.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,3.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,3.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,3.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,3.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,3.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,48.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,50.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,51.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,51.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,51.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,52.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,54.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,53.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,54.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,52.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,52.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,11.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,10.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,10.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,10.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,10.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,10.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,10.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,10.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,10.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,11.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,6.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,7.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,7.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,7.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,6.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,7.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,6.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,6.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,7.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,0.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,49.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,46.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,48.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,43.8
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,47.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,49.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,6.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,6.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,5.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,5.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,4.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,4.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,4.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,3.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,3.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,42.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,45.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,46.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,41.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,43
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,46.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,61.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,75.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,81.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,88.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,75.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,76.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,74.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,73.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,73.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,74.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,77.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,76.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,76.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,79.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,80.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,97.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,102.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,100
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,98.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,100.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,100.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,99.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,101.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,116
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,5.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,5.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,5.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,6.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,6.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,7.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,9.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,8.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,7.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,7.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,174.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,178.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,174.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,197.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,200.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,210.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,211.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,215.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,242.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,260
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,10.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,11.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,11.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,10.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,8.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,8.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,5.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,7.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,4.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,5.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,2.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,2.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,2.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,1.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,1.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,1.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,8.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,9.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,7.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,7.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,7.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,6.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,6.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,6.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,5.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,6.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,5.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,151.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,151.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,148.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,146.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,144
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,142.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,144.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,147.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,134.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,134.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,6.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,7.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,7.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,8.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,8.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,8.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,8.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,8.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,7.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,7.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,53.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,58.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,53.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,55
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,56.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,58.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,63.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,66.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,72.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,59.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,82.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,38
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,39.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,40.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,41.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,41.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,41
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,41.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,39.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,39.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,43
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,38.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,41.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,44.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,48.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,50.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,51.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,55.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,59.9
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,61.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,67.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,102.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,102.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,105.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,105.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,112.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,120.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,133.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,147.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,167.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,123.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,133.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,137.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,149.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,159.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,170.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,177
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,114.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,121
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,125.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,124.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,21.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,20.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,20.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,20.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,20.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,21.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,22.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,18.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,27.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,52.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,0.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,0.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,0.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,15.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,15.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,15.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,16.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,16.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,16.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,16.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,15.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,16.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,15.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,15.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,11.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,8.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,8.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,10.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,35.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,33.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,33.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,41
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,37.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,40
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,48.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,55
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,60.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,2.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,2.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,2.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,2.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,3.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,3.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,3.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,3.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,4.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,4.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,4.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,3.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,3.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,3.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,3.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,4.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,4.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,4.5
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,33.9
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,38.4
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,41.4
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,45.6
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,50.3
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,54.6
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,58
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,62.1
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,65.4
DNK,Denmark,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,70.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,28.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,26.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,27
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,28.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,28
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,28.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,29.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,30.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,28.7
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,28.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,22.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,24
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,24.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,25.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,27.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,27.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,29.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,31.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,32.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,33.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,32.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,83.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,85.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,87.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,90.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,90.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,93.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,94.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,93.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,93.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,94.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,89.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,19.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,19.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,19
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,19.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,21.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,21.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,22.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,21.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,19.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,19.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,65.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,60.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,61.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,60.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,63.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,65.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,67.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,72.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,78.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,81.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,109.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,112.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,118.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,125.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,132.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,137.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,146.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,156
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,165.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,179.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,12.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,12.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,12.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,12
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,11.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,11.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,11.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,11
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,10.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,10.7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,19.2
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,19.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,98.3
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,94.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,99.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,107
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,111.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,108.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,111.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,119
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,121.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,112.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,121.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,58.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,59.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,58.1
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,66.3
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,67
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,70.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,16.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,19.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,21.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,24.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,27.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,55.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,60.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,62.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,68.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,74
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,0.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,0.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,0.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,0.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,0.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,0.8
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,5.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,42
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,41.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,40.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,39.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,38.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,37.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,34.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,34.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,33.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,32.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,11.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,11.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,11.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,23.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,21.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,20.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,19.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,19
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,18.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,17.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,16.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,18.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,20.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,24
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,31.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,36.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,38.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,47.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,52.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,61.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,70.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,12.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,12
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,12.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,13.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,13.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,12.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,11.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,11.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,11.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,11.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,57
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,61.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,57.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,59.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,62.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,66.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,72.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,78.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,82.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,67.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,86.8
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,60.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,1.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,1.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,1.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,1.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,1.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,1.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,1.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,1.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,1.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,1.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,39.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,41
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,44.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,43.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,43.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,45.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,46.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,43.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,45.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,48.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,1.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,1.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,1.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,1.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,1.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,1.6
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,1.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,2.5
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,1.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,16.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,16.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,15.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,15.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,15.5
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,14
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,14.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,16.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,15.4
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,17.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,91.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,95.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,100.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,108.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,92.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,97.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,100
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,99.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,102.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,104.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,6.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,5.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,5.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,5.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,5.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,5.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,5.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,5.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,5.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,5.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,2.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,2.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,2.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,2.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,2.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,2.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,2.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,4.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,5.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,2.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,10.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,10.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,10.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,9.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,9.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,9.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,9.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,8.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,8.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,8.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,0.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,0.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,0.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,0.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,0.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,0.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,0.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,0.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.3
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,14
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,14
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,14.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,15
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,15.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,15
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,15.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,16.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,16
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,15.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,16.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,16.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,17
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,15.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,16.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,16.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,17.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,19.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,19.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,22.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,17.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,26.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,46.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,49.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,51.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,53.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,55
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,53.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,54.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,55.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,56.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,56.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,67.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,71.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,72.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,74.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,76.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,78.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,79.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,83.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,81
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,4.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,3.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,3.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,3.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,3.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,2.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,2.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,2.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,11.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,13.5
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,13.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,15.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,16.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,18.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,20.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,22.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,23.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,1.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,1.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,1.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,1.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,1.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,1.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,1.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,10.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,10.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,10.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,10.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,10.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,9.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,9.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,9.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,9.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.3
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,1.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,1.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,1.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,0.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,0.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,0.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,0.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,18.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,18.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,17.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,18.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,19.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,19.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,19.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,20.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,19.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,33.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,38.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,42.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,46
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,48.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,52
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,56.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,61.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,61.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,65.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,66
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,64.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,61.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,58.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,54.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,52
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,49.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,46.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,46.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,44
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,43
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,41.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,2.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,2.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,2.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,2.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,2.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,2.3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,3.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,2.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,32.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,33.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,33.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,35.3
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,36
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,37.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,38.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,41.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,39.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,42.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,108.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,113
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,111.1
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,111.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,110.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,103.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,206.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,211.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,221
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,50
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,49
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,48.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,48
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,46.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,45.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,44.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,44.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,43.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,42.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,3.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,3.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,3.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,3.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,3.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,4.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,5.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,5.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,6.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,104.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,104.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,107.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,108.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,109
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,110.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,111.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,118.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,115.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,120
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,124.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,80.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,79.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,77.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,74.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,74.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,71
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,70.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,72.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,69.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,68.2
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,66.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,51.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,56.3
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,62.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,67.8
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,79.4
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,84.5
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,92.1
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,101.9
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,108.7
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,111.6
LVA,Latvia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,113.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,72.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,78.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,80.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,83.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,88.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,89.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,89.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,100.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,102.3
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,104
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,48.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,50.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,51.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,53
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,55.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,56.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,58.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,59.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,65.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,76.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,88.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,28.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,28.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,28.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,27.5
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,27.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,26.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,25.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,25.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,23.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,22.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,22.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,75.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,77.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,79.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,82.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,84.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,87.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,91.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,94.6
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,98.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,104.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,109.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,10.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,10.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,10.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,10.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,9.8
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,9.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,9.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,8.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,8.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,9.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,26.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,30.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,33.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,35.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,37.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,39
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,42.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,43.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,45.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,51.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,7.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,7.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,7.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,7.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,7.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,8.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,8.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,85
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,83.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,86.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,80.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,81.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,83.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,88.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,100.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,98.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,103.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,74.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,70.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,67.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,65
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,61.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,59.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,57.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,56.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,54.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,53
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,51.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,20.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,28.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,25.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,26.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,26.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,27.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,23.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,24.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,24.9
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,23.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,17.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,19.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,23.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,24.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,23.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,24.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,26.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,28.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,29.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,31.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,40.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,45
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,45.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,46.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,46.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,47.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,47.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,48.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,50.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,50.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,2.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,2.6
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,2.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,2.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,19.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,19.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,19.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,18.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,18.6
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,18.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,18.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,15.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,18.2
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,20.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,20.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,21.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,21.2
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,21.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,22.6
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,23.9
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,26.8
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,29.1
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,28.7
LTU,Lithuania,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,29.4
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,293.9
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,270.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,236.6
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,253.2
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,247.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,244.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,21.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,22.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,23.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,24.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,25.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,26.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,27.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,28.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,29
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,29.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,107.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,157
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,159.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,157.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,87.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,106.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,121.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,196.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,202.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,200.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,174.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,284.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,266.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,258.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,256.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,251.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,235.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,229.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,224.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,225.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,225.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,227.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,10.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,10.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,10.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,9.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,9.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,9.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,8.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,6.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,6.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,7.7
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,47
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,46.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,47.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,47.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,48.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,47.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,48
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,49.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,51.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,52.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,51
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,73.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,74.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,72.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,71.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,69.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,70.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,71.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,72.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,71.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,70.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,18
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,19.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,20.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,20.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,20.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,20.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,21.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,21
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,20.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,21.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,10.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,9.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,9.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,9.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,8.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,8.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,8.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,6.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,6.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,7.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,4.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,4.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,3.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,3.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,3.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,4.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,5.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,18.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,16.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,15.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,15.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,16.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,18.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,18.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,15.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,15.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,17
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,2.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,2.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,2.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,1.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,2.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,2.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,2.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,2.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,23.2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,22.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,23.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,28.3
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,29.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,30
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,31.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,31.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,30.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,30.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,9.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,10.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,10.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,10
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,10.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,11
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,11.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,13.3
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,14.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,15.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,54.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,57.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,59.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,61.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,62.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,64.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,65
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,66.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,67.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,73.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,77.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,118
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,116.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,119.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,122.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,126
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,130.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,137.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,137.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,140.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,143.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,145
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,41
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,42
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,42.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,42.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,42.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,42.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,41.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,43.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,41.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,41.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,40
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,8.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,8.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,7.7
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,7.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,7.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,7.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,7.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,7.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,6.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,38.5
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,39.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,41
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,42.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,42.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,42.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,43.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,43.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,42.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,43.9
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,14.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,13.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,14.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,14.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,13
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,12.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,15.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,11
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,10.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,12.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,89
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,88.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,87.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,85.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,83.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,82.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,82.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,81.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,80.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,78.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,31.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,31.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,31.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,31.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,30.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,30
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,30.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,29.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,26.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,43.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,44.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,45.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,43.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,42.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,44
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,44.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,45.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,44.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,45.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,74.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,75.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,77.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,78.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,82.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,87.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,90.9
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,99.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,98.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,104.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,17.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,17.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,17.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,17
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,16.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,15.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,15.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,14.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,14.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,15.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,53.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,55.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,56.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,56.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,56.9
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,58.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,60.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,62.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,64
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,65.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,18.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,20.2
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,21.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,22.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,23.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,24.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,25.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,26.8
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,27.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,27
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,21.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,19.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,16.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,15.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,15.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,14.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,15.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,16.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,16.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,17.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,16
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,15.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,15.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,15.8
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,16.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,16.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,18.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,19.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,20.2
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,22.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,9.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,10
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,10.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,10.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,10.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,10.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,10.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,10.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,10.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,11.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,15.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,16.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,17.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,18.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,17.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,18
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,19.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,19.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,18.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,18.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,7.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,7.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,7.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,6.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,6.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,6.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,6.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,6.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,5.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,25.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,24.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,24.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,24
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,20.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,21.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,21.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,18.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,17.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,21.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,21.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,22
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,23.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,25
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,25.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,27.3
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,28.9
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,31.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,33.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,39.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,27.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,26.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,26.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,28
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,28
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,27.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,27.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,28.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,31.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,37.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,8.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,9.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,9.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,10.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,11.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,12.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,13.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,14.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,14.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,17.4
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,3.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,83.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,81.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,80
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,80.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,78.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,79.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,80.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,77.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,78.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,82.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,85.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,89.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,90.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,87.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,87.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,88.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,87.7
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,81.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,23.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,24.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,25
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,24.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,24.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,26.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,26.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,27.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,26.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,26.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,27
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,42.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,39
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,35.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,31.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,32.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,40.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,44.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,46.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,49.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,0.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,0.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,0.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,0.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,4.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,4.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,4.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,4.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,4.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,4.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,5.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,5.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,5.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,5.8
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,134.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,131.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,134
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,133.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,134.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,139
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,140.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,147.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,155.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,161.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,8.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,9.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,11.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,13.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,13.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,9.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,6.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,5.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,4.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,4.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,4.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,5.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,5.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,7.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,6.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,5.6
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,5.5
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
NZL,New Zealand,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,0
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,18.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,19.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,20.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,20.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,21
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,20.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,21
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,22.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,22.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,22.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,21.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,2.1
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,2.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,2.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,28.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,28
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,27.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,27.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,28.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,30
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,32.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,32.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,32.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,36.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,54.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,52.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,51.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,51.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,47.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,46.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,44.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,42.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,39.9
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,34.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,36.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,43.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,44.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,45.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2016,45.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,46.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,47.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,48
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,48.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,48.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,49.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,19.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,21.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,64.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,16.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,14.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,11.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,29.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,18.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,24.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,26.5
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,11.1
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,6.1
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,5.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,1.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,1.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,0.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,0.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,0.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,0.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,0.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,0.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,0.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,0.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,0
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2013,80.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2014,84.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2015,88
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2016,88.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2017,89.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2018,90.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,92.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,94.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,97.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,99.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,2.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,1.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.6
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,46.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,44.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,43.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,42.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,42
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,42.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,41.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,41.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,40.7
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,39.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,37.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,60.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,62.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,60.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,44.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,43
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,42.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,39.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,38.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,41.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,43.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,12.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,13.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,14.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,15.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,16.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,16.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,17.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,17.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,17.5
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,20.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,7.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,7.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,7.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,8.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,8.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,9.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,9.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,10.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,29.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,29.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,28.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,29.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,28.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,28.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,29.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,29.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,30.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,33.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,3.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,3.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,3.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,3.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,3.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,3.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,1.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,1.4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,1.6
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,1.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,1.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,3.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,3.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,3.3
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,3.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,3.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,3.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,3.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,15.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,15.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,15.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,15.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,15.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,14.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,12.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,9.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,9.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,10.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,63.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,66.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,65.5
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,65.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,66.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,67.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,68.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,70.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,72.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,73.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,67.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,68.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,69
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,68.9
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,68.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,68.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,68
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,67.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,72.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,82.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,3.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,3.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,4.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,3.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,3.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,3.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,2.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,220.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,225.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,230
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,233.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,240.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,253
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,264.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,274.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,281
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,33.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,34.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,34.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,35.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,35.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,36.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,37
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,37.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,37.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,37.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,37.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,5.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,5.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,5.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,5.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,4.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,4.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,4.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,4.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,3.8
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,4.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,5.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,6.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,7.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,9.1
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,6.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,7.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,95.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,101
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,101.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,105.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,107.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,110.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,107.8
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,109.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,112.5
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,116.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,105.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,25.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,24.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,23.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,23.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,21.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,21.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,20.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,19
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,16.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,87.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,89
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,89.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,88.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,87.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,89.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,94.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,99.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,106.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,111.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,117.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2013,44.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2014,44.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2015,48.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2017,55.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2018,58
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,61
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,65.8
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,70.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,73.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,76.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.4
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,74.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,77.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,79.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,83.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,86.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,90.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,95.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,101.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,106.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,113.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,122.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,18.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,19.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,19.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,18.7
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,18.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,17.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,17.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,14.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,14.6
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,16.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,14.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,16
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,17.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,19
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,20.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,22.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,23.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,25.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,27.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,29.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,8.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,8.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,8.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,8.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,8.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,9.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,9.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,9.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,9.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,8.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,1.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,1.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,38.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,40
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,42.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,21.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,20.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,20.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,19.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,21.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,20.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,21.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,34.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,31.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,27.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,28.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,27.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,21.9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,19.7
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,20.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,21.4
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,22.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,26.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,28.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,29.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,31.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,31.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,32.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,34.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,37.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,39.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,44.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,12.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,11.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,11.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,7.6
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,5.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,5.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,4.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,4.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,4.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,34.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,29
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,27.8
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,28.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,25.5
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,19.4
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,17.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,16.7
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,18.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,22.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,38
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,30.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,28.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,23.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,22.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,22.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,21.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,18.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,20.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,19.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,35.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,35.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,36.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,39
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,40.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,43.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,46.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,49.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,52.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,63.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,31.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,34.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,37.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,41
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,37.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,34.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,39.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,43.1
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,44.6
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,46.4
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,15.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,14.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,14.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,14.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,15
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,14.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,14.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,15
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,14.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,15
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,0.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,50.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,49.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,48.3
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,47.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,45.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,42
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,41.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,37.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,31
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,0
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,0
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,4.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,3.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,3.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,3.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,3.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,3.1
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,2.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,2.8
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,2.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,7.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,13.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,14.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,12.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,9.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,11.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,11.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,13.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,15.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,17
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,45.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,44.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,40
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,38
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,35.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,34
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,32.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,22.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,28
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,29.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,42.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,42.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,40.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,32.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,33.5
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,33.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,35.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,34.2
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,35.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,39.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,9.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,8.9
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,8.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,8.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,7.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,7.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,7.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,7.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,7.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,7.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,4.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,4.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,4.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,4.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,5.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,5.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,6.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,7.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,6.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,10.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,10.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,9.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,9.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,9.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,9.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,9.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,9.5
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,9.4
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,9.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,9.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,28.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,32.2
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,35.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,41.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,45.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,49.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,53.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,57.3
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,60.1
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,66.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,103.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,112.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,117.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,125.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,130.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,135.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,145.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,155.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,169.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,194.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,8.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,7.8
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,6.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,6.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,6.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,6.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,6.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,6.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,7.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,6.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,10.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,10.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,9.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,9.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,9.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,8.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,7.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,7.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2013,1.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2014,1.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2015,1.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2016,1.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2017,2.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2018,2.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,1.8
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,2.1
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,41.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,43.9
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,40.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,44.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,47.6
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,51.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,55
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,56.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,60.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,47.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,63.3
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,122.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,119.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,116.6
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,117.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,115.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,116.1
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,121.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,122.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,121.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,120.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,115.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,24.7
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,23.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,22.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,23.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,23.5
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,22.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,21.4
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,20.8
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,18.9
AUT,Austria,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,19.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,19.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,18.4
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,14.8
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,13.2
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,11.7
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,11.6
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,11.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,12
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,12.5
IRL,Ireland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,13.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,8.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,8.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,7.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,7.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,7.9
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,7.3
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,6.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,6.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,14
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,12.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,11.9
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,12.7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,13.2
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,13.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,13.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,14.5
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,15
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,8.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,1.3
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,1.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,1.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,1.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,1.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,111.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,118
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,124.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,134.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,144.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,169.3
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,170.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,152.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,188.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,214.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,2.8
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,3.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,3.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,3.4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,3.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,3.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,4.3
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,4
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,4.7
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,4.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,12.8
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,12.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,12.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,12.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,11.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,11
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,11.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,9.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,9.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,11.6
ROU,Romania,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,4.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,45
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,52.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,58.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,63.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,67.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,72.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,75.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,83.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,94
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,97.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,14.9
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,13.7
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,13.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,12.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,11.8
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,12.1
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,12.6
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,14
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,14.4
KOR,Korea,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,14.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2013,11.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2014,11.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2015,9.5
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2016,9.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2017,9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2018,9.4
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,10.2
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,10.1
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,10
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,10.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,24.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,23.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,25.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,24.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,25.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,26.7
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,26
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,29.1
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,29.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,28.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,5.5
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,4.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,4.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,4.7
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,4.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,6.2
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,7.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,8.4
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,7.9
SWE,Sweden,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,8.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2013,53
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2014,102.3
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2015,75
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2016,80.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2017,72.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2018,44.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,69.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,83
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,100.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,74
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,75.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,145.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,143.8
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,143.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,138.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,137.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,135.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,136.7
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,140.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,146.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,1.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,1.2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,1.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,1.1
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,1.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,1.4
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,2
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,1.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,1.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2013,1.9
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2014,2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2015,2.1
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2016,2.3
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2017,2.6
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2018,2.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,2.7
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,2.5
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,3.2
HRV,Croatia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,2.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,43.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,44.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,44.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,45.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,45
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,45.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,45.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,44.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,44.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,44.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,43.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2013,2.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2014,2.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2015,2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2016,1.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2017,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2018,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,2.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,4.3
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,32.1
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,30.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,5.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,5.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,5.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,5.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,4.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,4.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,4.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,4.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,4.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,4.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,4.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,4.4
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,4.8
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,5.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,5.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,6.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,6.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,0.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,1.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,0.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.1
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,0.3
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,0.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,0.5
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,0.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,0.6
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0.8
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0.7
EST,Estonia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,2.2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,2.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,2.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,2
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,2.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,3.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,3.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,3.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,3.3
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,2.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,2.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,2.7
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,2.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,2.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,2.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,2.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,2.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,1.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,1.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,1.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,1.4
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,1.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,1.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,1.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2015,1.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2016,1.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2017,1.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2018,1.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,1.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,1.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,1.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,1.2
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,3.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,3.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,2.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,2.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,2.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,2.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,2.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,3.4
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,3.4
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,53
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,54.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,59.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,59.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,66.6
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,75.8
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,76.2
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,76.5
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,83
TUR,Türkiye,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,86.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,50.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,51
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,49.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,50
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,49.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,51.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,53
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,53.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,53.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,54.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,67.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,71
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,73.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,64
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,64.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,65.1
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,65.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,66.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,65.3
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,65.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,46.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,51.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,54.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,59.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,65.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,71.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,75
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,71.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,79.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,88.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,0.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,0.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,0.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,0.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,0.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,0.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,0.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,90.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,92.4
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,94.5
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,96.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,92
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,93.2
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,102.8
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,104.3
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,107.9
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,110.7
PRT,Portugal,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,108.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,37.7
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,40.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,44.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,50.4
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,54.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,60.3
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,65
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,67.8
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,77.6
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,57.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,59.2
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,58.9
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,58.1
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,57.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,56
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,54.7
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,53.8
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,52.3
SVN,Slovenia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,50.8
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,25
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,23.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,23.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,22.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,22.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,22.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,21.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,16.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,15.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,19.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,3.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,3.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3.5
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,3.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,3.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,3.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,3.8
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,9.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,9.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,9.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,10.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,11.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,13
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,12.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,12.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,13.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,15
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,9.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,9.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,9.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,10.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,10.9
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,11
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,11.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,11.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,11.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,9.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,27.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,27.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,27.9
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,27.8
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,28.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,28.1
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,28.4
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,28.2
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,27.5
AUS,Australia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,26.5
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,37
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,40.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,43.7
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,46.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,49.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,53
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,56.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,60.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,65
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,78.9
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,78.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,10.4
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,10.2
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,10.7
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,11.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,10.9
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,11.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,9.6
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,9.3
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,10.5
CHL,Chile,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,9.7
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,151.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,151.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,151.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,151.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,149
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,148.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,151.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,152.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,154.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,155.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,8.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,8.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,8.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,9.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,10.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,11.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,11.6
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,12.3
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,13.2
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,11.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,18.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,18.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,19.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,21.3
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,21.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,23.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,25.7
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,28.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,30.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,37.2
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,23.1
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,25.1
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,27.8
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,31.8
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,35.3
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,38.6
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,40.2
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,43
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,47
CHE,Switzerland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,48.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,7.4
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,6.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,7
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,7.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,7.6
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,8.3
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,8.8
ISL,Iceland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,9.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,3.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,3.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,2.9
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,2.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,2.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,2.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,2.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,1.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,8.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,8.1
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,7.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,7.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,7.8
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,7.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,7.9
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,7.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,7.7
ITA,Italy,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,7.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,76.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,70.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,66.1
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,61.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,58
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,54.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,52.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,49.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,48.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,48.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,2.2
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,2.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,2.7
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,2.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,3.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,3.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,2.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,2.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,176.1
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,168.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,171
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,173.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,171.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,169.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,171.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,166.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,164.5
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,163.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2013,44.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2014,51
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2015,55
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2016,66.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2017,68
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2018,74.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,76.9
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,71.8
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,60.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,62
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,35.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,35.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,35.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,35.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,34.6
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,34.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,34.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,34.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,34.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,34.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,34.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,6.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,7.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2015,7.5
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2016,8.1
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2017,8.4
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2018,8.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,9.2
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,9.6
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,9.8
ITA,Italy,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,10.4
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2013,41.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2014,40.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2015,39.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2016,39
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2017,38.5
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2018,36.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,35.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,35.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,34.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,31.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,32.6
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,1.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,1.3
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,1.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,1.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,1.2
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,1.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,1.1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,1
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.9
LUX,Luxembourg,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.9
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,0
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,0
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,0
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,0
HRV,Croatia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,0
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,84.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,85.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,82.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,81.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,79.9
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,80.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,80.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,83.2
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,84.6
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,3.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,3.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,3.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,3.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.8
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,20.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,19.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,20.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,22.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,22.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,22.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,24.7
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,25.5
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,24
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,26.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,195.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,197.3
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,197.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,197.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,197.5
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,197.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,198.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,199.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,196.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,197.4
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,8.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,8.3
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,8.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,9.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,9.6
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,9.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,9.7
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,10.5
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,11.1
SVK,Slovak Republic,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,11
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2013,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2014,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2015,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2016,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2017,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2018,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2013,3.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2014,3.3
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2015,3.1
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2016,2.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2017,2.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2018,2.4
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,2.2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2020,2
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2021,1.8
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2022,1.6
ESP,Spain,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2023,1.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,50.4
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,49.6
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,48.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,47.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,45.1
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,44.9
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,43.2
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,26.5
LUX,Luxembourg,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,24.7
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,0.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,129.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,138
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,126.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,130.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,135.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,144.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,153
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,164
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,171.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,107.3
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,146.1
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,16.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,16.3
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,16
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,16.4
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,15.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,15.6
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,15.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,14
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,13.9
PRT,Portugal,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,16.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,136.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,128.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,138.4
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,68.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,82.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,71
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,73
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,78.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,75.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,83.1
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,134.7
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,136.4
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,139
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,141.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,149
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,156.2
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,162
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,168.6
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,173.8
GBR,United Kingdom,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,181.4
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2013,0
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2014,0
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,20.1
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,19.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,4.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,4.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,4.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,4
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,4.1
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,3.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,3.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,3.5
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,3.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,3.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,3.8
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,69.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,66.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,65.6
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,65.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,64.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,62.1
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,61.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,66.7
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,73.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,72.2
ISL,Iceland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,73.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,3.9
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,3.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,3.8
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,4.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,4.1
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,4.4
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,5.7
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,5.2
GRC,Greece,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,4.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,5.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,5.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,4.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,3.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,3.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,3.4
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,3.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.8
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,2.5
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.1
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.2
TUR,Türkiye,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,189.3
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,191.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,196.4
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,193.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,198.6
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,202.2
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,203.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,209.7
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,207.1
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,213.9
EST,Estonia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,210.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2013,4.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2014,2.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2015,2.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2016,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2017,1.3
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2018,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,1.1
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,1.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,23.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,21.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,24.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,23.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,20
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,22
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,19.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,14.4
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,16
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,20.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,2.4
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,2.3
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,2.2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,2
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,1.9
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,1.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,1.8
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,1.5
HUN,Hungary,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,1.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,51.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,53.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,54.6
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,55.1
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,54
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,56.3
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,56.4
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,56
FIN,Finland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,55.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2013,68.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2014,72.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2015,75.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2016,77.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2017,78.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2018,107.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,112.2
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,116
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,117.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,118.3
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,30.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,31.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,32.2
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,31.7
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,31.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,31.8
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,30.5
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,31.6
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,32.1
ISR,Israel,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,32.6
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2013,7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2014,6.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,1.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,1.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,1.9
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,1.6
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,1.5
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,1.7
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,1.8
NZL,New Zealand,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,2.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2013,26.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2014,26.9
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2015,26.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2016,28
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2017,28.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2018,29.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,31.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,31.1
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,36.8
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,38.2
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,10.6
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,10.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2015,8.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2016,9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2017,8.4
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2018,7.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,7.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,7.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,7.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,9.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2013,0.2
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2014,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2015,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2016,0.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2017,0.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2018,0.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,0.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,0.5
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2013,19.9
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2014,20
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2015,20
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2016,19.7
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2017,19
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2018,18.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2019,18.4
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2020,19.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2021,22.3
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,24.2
DNK,Denmark,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,26.2
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,17.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,15.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,14
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,13.9
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,12.4
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,11.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,10.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,10.1
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,10.6
AUS,Australia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,10.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,13.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,13.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,13.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,13.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,13.4
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,13.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,14
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,14.3
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,14.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,14.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,16.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,13.4
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,13.7
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,17.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,10.9
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,10.2
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,10.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,11.4
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,11.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,10.5
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,9.7
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,9.1
FIN,Finland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,8.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2013,1.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2014,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2015,1.3
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2016,1.4
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2017,1.5
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2018,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,1.8
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,1.6
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,3.1
CRI,Costa Rica,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,2.8
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2013,2.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2014,2.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2015,2.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2016,2.4
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2017,2.6
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2018,2.7
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.1
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.3
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.2
LVA,Latvia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,130.1
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,130.9
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,133.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2016,136.3
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,137.5
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,141.8
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,147.6
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,152.2
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,159.4
BEL,Belgium,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,168.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2013,17.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2014,16.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2015,16.8
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2016,16.2
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2017,15.7
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2018,15.3
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2019,14.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2020,13.9
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2021,14
NOR,Norway,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,J01,Antibacterials for systemic use,2022,15.3
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2013,30.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2014,32
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2015,32.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2016,32.9
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2017,32.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2018,38.7
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,40.8
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,40.5
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,40.1
ESP,Spain,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,44.2
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2013,9.8
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2014,9.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2015,9.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2016,9.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2017,9.1
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2018,8.6
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,8.7
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,8.5
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,8.3
FRA,France,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,8.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,40.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,40.1
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,39.7
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,39
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,36.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,36.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,36.6
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,34.8
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,35.5
DEU,Germany,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,38.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2013,15.4
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2014,15
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2015,14.5
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2016,13.8
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2017,12.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2018,11.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,11.3
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,10.7
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,10
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,9.9
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,9.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2013,24.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2014,23.9
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2015,24
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2016,22.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2017,21.5
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2018,21.4
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,22.6
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,20.1
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,17.3
BEL,Belgium,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,20.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2013,32.5
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2014,33.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2015,33.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2016,20.6
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2017,20
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2018,19.8
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,18.9
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,18.2
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,16.7
SVK,Slovak Republic,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,16.4
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2013,12.1
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2014,13
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2015,14.2
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2016,14.9
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2017,15.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2018,16.6
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,9.7
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,9.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,9.5
NLD,Netherlands,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,9.5
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2013,9.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2014,9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2015,8.8
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2016,15.2
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2017,15.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2018,14.1
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,14.3
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,14.4
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,15.6
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,15.9
CAN,Canada,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,17.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2013,9.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2014,8.1
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2015,6.7
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2016,7.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2017,6.3
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2018,5.9
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,6.2
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,5.5
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,5.6
CZE,Czechia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,5.7
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2013,0.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2014,0.9
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2015,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2016,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2017,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2018,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.8
SVN,Slovenia,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2013,13.1
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2014,12.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2015,12.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2016,12.5
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2017,12
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2018,10.6
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,9.2
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,9
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,8.8
CAN,Canada,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,8.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,247.8
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,253.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,256.2
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,255
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,255.3
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,250.5
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,252.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,254.6
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,251.9
CZE,Czechia,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,253.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,13.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,14.3
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,15.2
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,17.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,19.5
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,21.6
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,23.7
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,26.4
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,37.1
NOR,Norway,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,45.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2013,347.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2014,359
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2015,363.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2016,363.9
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2017,365.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2018,367.4
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,369.7
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,384.3
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,371.1
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,370.6
HUN,Hungary,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,367.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2013,14.5
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2014,15.6
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2015,17.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2016,19.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2017,21.3
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2018,24.7
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,26.9
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,30.2
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,32.1
KOR,Korea,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,35.7
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2013,6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2014,6.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2015,6.4
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2016,6.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2017,6.3
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2018,6.2
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,6.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,6.6
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,6.5
DEU,Germany,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,6.7
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2013,6
NLD,Netherlands,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2014,5.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2013,2.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2014,2.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2015,2.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2016,2.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2017,2.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2018,2.1
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2019,2.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2020,2.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2021,2.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2022,2.2
SWE,Sweden,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,2
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2013,102.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2014,99
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2015,104.6
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2017,116
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2018,123.7
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,131
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,141.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,150.9
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,165.4
GRC,Greece,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,175.8
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2013,40.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2014,39.6
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2015,30.2
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2016,17.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2017,16.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2018,16.1
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,16.5
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,16.4
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,16
AUT,Austria,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,15.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2013,30.2
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2014,33.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2015,39
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2016,35.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2017,32.9
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2018,36.8
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,38.7
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,56.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,67.4
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,71.6
CHL,Chile,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,70.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2013,36.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2014,38.5
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2015,34.2
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2016,35.4
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2017,36.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2018,37.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,38.8
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,50.7
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,54.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,45.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,59.3
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,4.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,5.3
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,4.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,6.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,9.3
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,9.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,10.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,9.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,0.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2019,3.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2020,3.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2021,3.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2022,3.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01B,"Antiarrhythmics, Class I and III",2023,3.9
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2019,11.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2020,10.7
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2021,11.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",B,Blood and blood forming organs,2022,12.4
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,3.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,3.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.9
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,2.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,1.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,1.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,1.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,1.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2019,20.1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2020,18.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2021,19
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2022,20.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,M01A,Antiinflammatory and antirheumatic products non-steroids,2023,20.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2019,23.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2020,26.9
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2021,30.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2022,35
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N06A,Antidepressants,2023,39.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,0
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2019,0
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2020,0
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2021,0
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02A,Antacids,2022,0
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,4.6
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,4.9
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,4.6
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,4.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,20.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,19.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,20
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,20.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,20.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,23.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,24.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,27.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,1.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,1.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,1.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,7.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,7.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,7.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,7.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2019,19.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2020,21.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2021,22.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A10,Drugs used in diabetes,2022,27.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2019,37.9
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2020,40.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2021,40.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2022,40.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C07,Beta blocking agents,2023,41.9
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2019,9
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2020,8.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2021,8.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2022,8.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,G03,Sex hormones and modulators of the genital system,2023,8.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2019,6.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2020,6.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2021,7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2022,7.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N02,Analgesics,2023,7.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,4.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,4.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,4.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2019,19.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2020,19.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2021,20.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",R03,Drugs for obstructive airway diseases,2022,22.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2019,45.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2020,45.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2021,42.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2022,42.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C08,Calcium channel blockers,2023,41.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2019,3.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2020,3.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2021,3.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C03,Diuretics,2022,3.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,2.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,1.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,1.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,1.1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,44.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,44.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,46.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,47.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2023,48.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,2.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,3.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,3.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,3.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2019,37.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2020,37.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2021,34.9
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2022,33.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C03,Diuretics,2023,32.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,5.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,5.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,4.9
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2019,4.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2020,4.6
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2021,4.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N02,Analgesics,2022,4.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,37.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,39.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,39.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,42.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,H,"Systemic hormonal preparations, excluding sex hormones and insulins",2023,40.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2019,0.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2020,0.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2021,0.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01A,Cardiac glycosides,2022,0.1
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2019,1.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2020,1.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2021,2.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05C,Hypnotics and sedatives,2022,2.6
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2019,0.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2020,0.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2021,0.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N05B,Anxiolytics,2022,0.1
CRI,Costa Rica,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A02A,Antacids,2023,0.4
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,4.4
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,5.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,5.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,6.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2019,3
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2020,4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2021,4.9
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",A02B,Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),2022,5.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2019,73.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2020,76.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2021,77.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2022,82.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,A10,Drugs used in diabetes,2023,88.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2019,2.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2020,2.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2021,2.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",G03,Sex hormones and modulators of the genital system,2022,2.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2019,82.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2020,81.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2021,88.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2022,94.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,B,Blood and blood forming organs,2023,96.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2019,3.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2020,2.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2021,2.7
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",M01A,Antiinflammatory and antirheumatic products non-steroids,2022,2.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2019,19.4
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2020,19.7
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2021,18.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C09,Agents acting on the Renin-Angiotensin system,2022,18.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2019,10.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2020,10.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2021,10.6
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C10,Lipid modifying agents,2022,11.1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C01A,Cardiac glycosides,2019,0.1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2019,8.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2020,8.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2021,8.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2022,8.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C02,Antihypertensives,2023,9.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2019,0.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2020,0.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2021,0.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2022,0.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05B,Anxiolytics,2023,0.2
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2022,0
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,N05C,Hypnotics and sedatives,2023,0
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2019,4.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2020,4.8
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2021,4.4
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",H,"Systemic hormonal preparations, excluding sex hormones and insulins",2022,4.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2019,0.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2020,0.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2021,0.2
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C01B,"Antiarrhythmics, Class I and III",2022,0.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2019,43.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2020,43.6
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2021,44.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2022,46.1
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,R03,Drugs for obstructive airway diseases,2023,44.3
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2019,9.1
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2020,6.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2021,7.2
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",J01,Antibacterials for systemic use,2022,8.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2019,1.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2020,1.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2021,1.8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C07,Beta blocking agents,2022,1.6
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2019,2.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2020,2.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2021,2.7
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C08,Calcium channel blockers,2022,2.7
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2019,1.5
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2020,1.6
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2021,1.4
POL,Poland,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",C02,Antihypertensives,2022,1.4
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2019,246.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2020,254.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2021,250.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2022,253.7
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C09,Agents acting on the Renin-Angiotensin system,2023,259.3
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2019,116.8
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2020,125
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2021,130
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2022,141.5
POL,Poland,PH_CON,Pharmaceutical consumption,DDD_10P3HB,Defined daily doses per 1 000 inhabitants per day,C10,Lipid modifying agents,2023,155.4
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2019,4.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2020,8
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2021,6.5
GBR,United Kingdom,PH_SALES,Pharmaceutical sales,USD_PPP_PS,"US dollars per person, PPP converted",N06A,Antidepressants,2022,5.2